Public change history

Changes and corrections

PeptideScanner corrections, routine public-version updates, and source-published research-integrity notices remain separate. Earlier public versions remain available rather than being silently erased.

Material record

Corrections and retractions

Factual errors, withdrawals, and retractions appear here separately from routine wording or source updates.

  1. Correction

    Abaloparatide profile

    We refreshed this profile's label citation to the reviewed SPL version 19, published 2026-08-17. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Cited source records

    Before
    dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18
    After
    dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18]
    After
    U.S. National Library of Medicine [sources: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19]

    Claim citations

    Before
    name: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18; aliases: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18; category: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18; status: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18; summary: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18; evidenceNote: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v18
    After
    name: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; aliases: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; category: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; status: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; summary: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; evidenceNote: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19
  2. Correction

    CJC-1295 profile

    We clarified that CJC-1295 with DAC is a related, distinct active moiety rather than an interchangeable form. The FDA briefing describes five bulk substances; clinical findings must retain the studied form.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A peptide named in FDA compounding-risk and DOJ enforcement records.
    After
    FDA evaluates CJC-1295 and CJC-1295 with drug affinity complex (DAC) as distinct active moieties, with several salt forms.

    Evidence note

    Before
    FDA's compounding-risk page describes immunogenicity, impurity, and adverse-event concerns. A separate Justice Department release names CJC 1295 among unapproved new drugs distributed by the cited pharmacy.
    After
    FDA's 2024 briefing distinguishes five bulk substances and reports that none is a component of an FDA-approved drug. Evidence for a DAC-modified substance cannot automatically establish effects for a non-DAC form.

    Cited source records

    Before
    fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement
    After
    fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-cjc-1295-briefing-2024

    Claim citations

    Before
    name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; evidenceNote: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement
    After
    name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-cjc-1295-briefing-2024; evidenceNote: fda-cjc-1295-briefing-2024
  3. Correction

    Dulaglutide profile

    We refreshed this profile's label citation to the reviewed SPL version 62, published 2026-08-10. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Cited source records

    Before
    dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v60
    After
    dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v60]
    After
    U.S. National Library of Medicine [sources: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62]

    Claim citations

    Before
    name: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v60; aliases: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v60; category: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v60; status: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v60; summary: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v60; evidenceNote: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v60
    After
    name: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62; aliases: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62; category: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62; status: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62; summary: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62; evidenceNote: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62
  4. Correction

    Elamipretide profile

    The previous profile described elamipretide only as investigational. We added FDA's September 19, 2025 accelerated approval of Forzinity for the specified Barth syndrome population. This correction does not extend that approval to other uses or formulations.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Status

    Before
    Investigational
    After
    U.S. accelerated approval for a specified Barth syndrome population

    Status classification

    Before
    investigational
    After
    approved

    Profile summary

    Before
    A mitochondria-targeting peptide candidate. This profile cites a recruiting ClinicalTrials.gov study record.
    After
    FDA granted Forzinity (elamipretide) accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.

    Evidence note

    Before
    ClinicalTrials.gov lists the 4TAZPower study as recruiting, updated July 13, 2026.
    After
    FDA's September 19, 2025 approval letter requires a confirmatory trial to verify clinical benefit. The approval concerns this product and specified use; a recruiting trial record does not describe its full regulatory status.

    Related names

    Before
    SS-31, MTP-131
    After
    SS-31, MTP-131, Forzinity

    Cited source records

    Before
    ctg-nct07531251-v4
    After
    ctg-nct07531251-v4, fda-forzinity-approval-2025

    Claim citations

    Before
    name: ctg-nct07531251-v4; aliases: ctg-nct07531251-v4; category: ctg-nct07531251-v4; status: ctg-nct07531251-v4; summary: ctg-nct07531251-v4; evidenceNote: ctg-nct07531251-v4
    After
    name: ctg-nct07531251-v4; aliases: ctg-nct07531251-v4, fda-forzinity-approval-2025; category: ctg-nct07531251-v4; status: fda-forzinity-approval-2025; summary: fda-forzinity-approval-2025; evidenceNote: fda-forzinity-approval-2025
  5. Correction

    Elamipretide profile

    We added a preserved FDA-hosted product label to support the product-specific label account. Prior profile versions retain their original citations.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Cited source records

    Before
    ctg-nct07531251-v4, fda-forzinity-approval-2025
    After
    ctg-nct07531251-v4, fda-forzinity-approval-2025, fda-forzinity-label-2025
  6. Correction

    Emideltide profile

    We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Status

    Before
    FDA compounding safety review; final determination pending
    After
    FDA compounding assessment in the cited records

    Evidence note

    Before
    FDA's emideltide briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
    After
    FDA's July 2026 briefing evaluates Emideltide-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.

    Claim citations

    Before
    name: fda-emideltide-briefing; aliases: fda-emideltide-briefing; category: fda-emideltide-briefing, fda-pcac-peptide-meeting-2026; status: fda-emideltide-briefing, fda-pcac-peptide-meeting-2026; summary: fda-emideltide-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-emideltide-briefing, fda-pcac-peptide-meeting-2026
    After
    name: fda-emideltide-briefing; aliases: fda-emideltide-briefing; category: fda-emideltide-briefing, fda-pcac-peptide-meeting-2026; status: fda-emideltide-briefing; summary: fda-emideltide-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-emideltide-briefing
  7. Correction

    Epitalon profile

    We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Status

    Before
    FDA compounding safety review; final determination pending
    After
    FDA compounding assessment in the cited records

    Evidence note

    Before
    FDA's Epitalon briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
    After
    FDA's July 2026 briefing evaluates epitalon free base and acetate and distinguishes the tetrapeptide from epithalamin, a pineal-gland extract. The briefing is an advisory-process assessment, not a final regulatory determination.

    Related names

    Before
    None recorded
    After
    AEDG, Epithalon

    Claim citations

    Before
    name: fda-epitalon-briefing; aliases: fda-epitalon-briefing; category: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026; status: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026; summary: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026
    After
    name: fda-epitalon-briefing; aliases: fda-epitalon-briefing; category: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026; status: fda-epitalon-briefing; summary: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-epitalon-briefing
  8. Correction

    Glucagon profile

    The previous summary described this only as an emergency-treatment label. We now distinguish Gvoke's severe-hypoglycemia indication from Gvoke VialDx's diagnostic indication in the same cited label.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A peptide hormone. This profile cites a U.S. emergency-treatment label.
    After
    A peptide hormone. The cited U.S. label distinguishes Gvoke for severe hypoglycemia from Gvoke VialDx for diagnostic use.

    Evidence note

    Before
    The cited DailyMed label identifies Glucagon and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    The cited label describes subcutaneous Gvoke for severe hypoglycemia in people with diabetes aged two years and older, and intravenous Gvoke VialDx as a diagnostic aid in adults. The product, route and indication must remain distinct.
  9. Correction

    Ipamorelin profile

    We added FDA's dated assessment to distinguish substance forms, evaluated uses and the advisory stage of review. Earlier profile versions remain available.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A peptide named in FDA compounding-risk and DOJ enforcement records.
    After
    FDA's August 2024 assessment distinguishes ipamorelin free base and acetate and evaluates evidence for growth hormone deficiency and postoperative ileus.

    Evidence note

    Before
    FDA's compounding-risk page describes immunogenicity and characterization concerns. A separate Justice Department release names Ipamorelin among unapproved new drugs distributed by the cited pharmacy.
    After
    At the time of its assessment, FDA reported that neither form was a component of an FDA-approved drug and found insufficient evidence for the evaluated uses. The advisory briefing is not a final compounding determination.

    Cited source records

    Before
    fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement
    After
    fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-ipamorelin-briefing-2024

    Claim citations

    Before
    name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; evidenceNote: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement
    After
    name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-ipamorelin-briefing-2024; evidenceNote: fda-ipamorelin-briefing-2024
  10. Correction

    KPV profile

    We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Status

    Before
    FDA compounding safety review; final determination pending
    After
    FDA compounding assessment in the cited records

    Evidence note

    Before
    FDA's KPV briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
    After
    FDA's July 2026 briefing evaluates KPV-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.

    Related names

    Before
    None recorded
    After
    Lys-Pro-Val

    Claim citations

    Before
    name: fda-kpv-briefing; aliases: fda-kpv-briefing; category: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; status: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; summary: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-kpv-briefing, fda-pcac-peptide-meeting-2026
    After
    name: fda-kpv-briefing; aliases: fda-kpv-briefing; category: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; status: fda-kpv-briefing; summary: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-kpv-briefing
  11. Correction

    Lixisenatide profile

    We added a preserved FDA-hosted product label to support the product-specific label account. Prior profile versions retain their original citations.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Cited source records

    Before
    dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25
    After
    dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25, fda-adlyxin-label-2024
  12. Correction

    Mazdutide profile

    The previous profile used an unqualified investigational status. We added dated local-government reports of approval in China while keeping national decision and label verification open. Earlier trial-based versions remain available.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Status

    Before
    Investigational
    After
    China: approval reported by local government sources

    Status classification

    Before
    investigational
    After
    approval-reported

    Profile summary

    Before
    A metabolic peptide candidate. This profile cites a ClinicalTrials.gov study record that was not yet recruiting.
    After
    A June 2025 Suzhou Industrial Park regulator report describes Chinese approval of mazdutide injection for long-term weight management in adults with obesity or overweight. A December 2025 Suzhou government report describes approved diabetes and weight-management indications in China.

    Evidence note

    Before
    ClinicalTrials.gov lists a West China Hospital study as not yet recruiting, updated July 21, 2026.
    After
    These are attributable local-government reports, not the national approval decision or complete prescribing information. The national decision and exact indication conditions remain to be reconciled. This account does not establish approval in the United States or other jurisdictions.

    Cited source records

    Before
    ctg-nct07718126-v1
    After
    ctg-nct07718126-v1, sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025

    Claim citations

    Before
    name: ctg-nct07718126-v1; aliases: ctg-nct07718126-v1; category: ctg-nct07718126-v1; status: ctg-nct07718126-v1; summary: ctg-nct07718126-v1; evidenceNote: ctg-nct07718126-v1
    After
    name: ctg-nct07718126-v1; aliases: ctg-nct07718126-v1; category: ctg-nct07718126-v1; status: sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025; summary: sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025; evidenceNote: sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025
  13. Correction

    MOTS-c profile

    We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Status

    Before
    FDA compounding safety review
    After
    FDA compounding assessment in the cited records

    Evidence note

    Before
    FDA presented MOTS-c briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
    After
    FDA's July 2026 briefing evaluates MOTS-c-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.

    Claim citations

    Before
    name: fda-mots-c-briefing; aliases: fda-mots-c-briefing; category: fda-bulk-peptide-risks, fda-mots-c-briefing; status: fda-mots-c-briefing, fda-pcac-peptide-meeting-2026; summary: fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-mots-c-briefing, fda-pcac-peptide-meeting-2026
    After
    name: fda-mots-c-briefing; aliases: fda-mots-c-briefing; category: fda-bulk-peptide-risks, fda-mots-c-briefing; status: fda-mots-c-briefing; summary: fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-mots-c-briefing
  14. Correction

    Semax profile

    We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Status

    Before
    FDA compounding safety review; final determination pending
    After
    FDA compounding assessment in the cited records

    Evidence note

    Before
    FDA's Semax briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
    After
    FDA's July 2026 briefing evaluates Semax-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.

    Claim citations

    Before
    name: fda-semax-briefing; aliases: fda-semax-briefing; category: fda-semax-briefing, fda-pcac-peptide-meeting-2026; status: fda-semax-briefing, fda-pcac-peptide-meeting-2026; summary: fda-semax-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-semax-briefing, fda-pcac-peptide-meeting-2026
    After
    name: fda-semax-briefing; aliases: fda-semax-briefing; category: fda-semax-briefing, fda-pcac-peptide-meeting-2026; status: fda-semax-briefing; summary: fda-semax-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-semax-briefing
  15. Correction

    TB-500 profile

    We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Status

    Before
    FDA compounding safety review; final determination pending
    After
    FDA compounding assessment in the cited records

    Evidence note

    Before
    FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.
    After
    FDA's July 2026 briefing evaluates TB-500-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.

    Claim citations

    Before
    name: fda-tb-500-identity, fda-tb-500-briefing; aliases: fda-tb-500-identity, fda-tb-500-briefing; category: fda-tb-500-briefing; status: fda-tb-500-briefing, fda-pcac-peptide-meeting-2026; summary: fda-tb-500-identity, fda-tb-500-briefing; evidenceNote: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026
    After
    name: fda-tb-500-identity, fda-tb-500-briefing; aliases: fda-tb-500-identity, fda-tb-500-briefing; category: fda-tb-500-briefing; status: fda-tb-500-briefing; summary: fda-tb-500-identity, fda-tb-500-briefing; evidenceNote: fda-tb-500-briefing
  16. Correction

    Tesamorelin profile

    We refreshed this profile's label citation to the reviewed SPL version 9, published 2026-07-31. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Cited source records

    Before
    dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8
    After
    dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8]
    After
    U.S. National Library of Medicine [sources: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9]

    Claim citations

    Before
    name: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8; aliases: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8; category: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8; status: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8; summary: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8; evidenceNote: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8
    After
    name: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; aliases: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; category: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; status: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; summary: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; evidenceNote: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9
  17. Correction

    Tirzepatide profile

    We refreshed this profile's label citation to the reviewed SPL version 40, published 2026-09-02. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile

    Cited source records

    Before
    dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023, fda-tirzepatide-identity
    After
    dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-tirzepatide-2023, fda-tirzepatide-identity

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38]
    After
    U.S. National Library of Medicine [sources: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40]

    Claim citations

    Before
    name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; aliases: fda-tirzepatide-identity; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38
    After
    name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; aliases: fda-tirzepatide-identity; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-tirzepatide-2023; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40

Version history

Editorial and source updates

These entries preserve wording changes or ordinary source-record updates. An entry here does not by itself mean the earlier version contained a factual error.

  1. Profile updated

    GHRP-2 profile

    We added FDA’s May 2026 503A nominations list, which places GHRP-2 in category 3, and two human studies of its effect on growth hormone and appetite and its use as a diagnostic test.

    PeptideScanner change date
    November 16, 2026
    Evidence lane
    Profile

    Evidence note

    Before
    FDA reports serious adverse events in patients who received GHRP-2, with causality not established. No FDA approval is reported in the cited sources, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
    After
    Small human studies report that GHRP-2 raises growth hormone and appetite, and test it as a diagnostic. FDA reports serious adverse events in patients who received GHRP-2, with causality not established. No FDA approval is reported, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.

    Cited source records

    Before
    fda-ghrp-2-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
    After
    fda-ghrp-2-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026, fda-503a-nominations-2026-05-14, journal-pmid-17609397, journal-pmid-16861611

    Claim citations

    Before
    name: fda-ghrp-2-identity, fda-bulk-peptide-risks; aliases: fda-ghrp-2-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-ghrp-2-identity, fda-bulk-peptide-risks; evidenceNote: fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
    After
    name: fda-ghrp-2-identity, fda-bulk-peptide-risks; aliases: fda-ghrp-2-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-ghrp-2-identity, fda-bulk-peptide-risks; evidenceNote: journal-pmid-16861611, journal-pmid-17609397, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
  2. Profile updated

    Insulin glargine-aldy profile

    We now state that the label calls Langlara biosimilar to Lantus, and that the trials in its label are the reference product’s trials, which the Lantus label describes as trials of Lantus. We also no longer suggest that an unread page of the approval letter might hold FDA’s findings: it does not.

    PeptideScanner change date
    November 16, 2026
    Evidence lane
    Profile

    Evidence note

    Before
    FDA’s approval letter describes the application as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus. The clinical studies in the label are insulin glargine studies against NPH insulin, not trials of insulin glargine-aldy itself.
    After
    Its label states that it is biosimilar to Lantus. The trials in the label are the insulin glargine trials against NPH insulin, which the Lantus label describes as trials of Lantus; no trial of insulin glargine-aldy itself is described in the sources reviewed here.

    Cited source records

    Before
    dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026
    After
    dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026, fda-lantus-label-2023

    Claim citations

    Before
    name: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; aliases: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; category: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; status: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; summary: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; evidenceNote: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-langlara-approval-2026
    After
    name: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; aliases: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; category: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; status: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; summary: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; evidenceNote: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-lantus-label-2023, fda-langlara-approval-2026
  3. Profile updated

    LL-37 profile

    We added three randomized trials of LL-37 in chronic ulcers, FDA’s advisory committee page listing LL-37 for a meeting before the end of February 2027, and the spelling LL37 that trial registrations use, so that those registrations are matched.

    PeptideScanner change date
    November 16, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A 37-amino-acid human cathelicidin peptide, also called ropocamptide, that FDA lists among compounding substances that may present significant safety risks.
    After
    A 37-amino-acid human cathelicidin peptide, also called ropocamptide, tested in small trials in chronic ulcers. FDA lists it among compounding substances that may present significant safety risks.

    Evidence note

    Before
    FDA states that it lacks sufficient safety information on LL-37 in people and cites nonclinical findings of harm to male reproduction and tumor promotion. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
    After
    Three small randomized trials in chronic leg and foot ulcers report mixed results; the largest found no significant difference from placebo. FDA states that it lacks sufficient safety information on LL-37 in people. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.

    Related names

    Before
    Cathelicidin LL-37, Ropocamptide
    After
    Cathelicidin LL-37, Ropocamptide, LL37

    Cited source records

    Before
    fda-ll-37-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
    After
    fda-ll-37-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026, fda-pcac-503a-meeting-2027, journal-pmid-25041740, journal-pmid-34687253, journal-pmid-37480520, ctg-observation-nct02225366-2021-12-09-d146b413ecf5

    Claim citations

    Before
    name: fda-ll-37-identity, fda-bulk-peptide-risks; aliases: fda-ll-37-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-ll-37-identity, fda-bulk-peptide-risks; evidenceNote: fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
    After
    name: fda-ll-37-identity, fda-bulk-peptide-risks; aliases: fda-ll-37-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-ll-37-identity, fda-bulk-peptide-risks, journal-pmid-34687253; evidenceNote: journal-pmid-34687253, journal-pmid-25041740, journal-pmid-37480520, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
  4. Profile updated

    Melanotan II profile

    We added two early human studies of Melanotan II and FDA’s advisory committee page listing it for a meeting before the end of February 2027.

    PeptideScanner change date
    November 16, 2026
    Evidence lane
    Profile

    Evidence note

    Before
    FDA cites published case reports of melanoma, brain swelling, stimulant-like toxicity and priapism in people who used Melanotan II. No FDA approval is reported in the cited sources, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
    After
    Two very small early human studies, one placebo-controlled in 10 men, report skin darkening, erections and nausea. FDA cites case reports of melanoma, brain swelling, stimulant-like toxicity and priapism. No FDA approval is reported, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.

    Cited source records

    Before
    fda-melanotan-ii-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
    After
    fda-melanotan-ii-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026, fda-pcac-503a-meeting-2027, journal-pmid-8637402, journal-pmid-11018622

    Claim citations

    Before
    name: fda-melanotan-ii-identity, fda-bulk-peptide-risks; aliases: fda-melanotan-ii-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-melanotan-ii-identity, fda-bulk-peptide-risks; evidenceNote: fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
    After
    name: fda-melanotan-ii-identity, fda-bulk-peptide-risks; aliases: fda-melanotan-ii-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-melanotan-ii-identity, fda-bulk-peptide-risks; evidenceNote: journal-pmid-8637402, journal-pmid-11018622, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
  5. Profile updated

    Octreotide profile

    We added the FDA labels of Sandostatin LAR and Mycapssa and now describe each trial with the octreotide product it tested, because the generic label cited on this page has no clinical studies section.

    PeptideScanner change date
    November 16, 2026
    Evidence lane
    Profile

    Evidence note

    Before
    The cited label states that its trials did not show improvement in symptoms or tumor size. Smaller randomized trials in acromegaly report lower growth hormone and IGF-1 levels.
    After
    The generic label cited here describes no trials of its own and states that its trials did not show improvement in symptoms or tumor size. Randomized trials of two other octreotide products, Sandostatin LAR and Mycapssa, are described in their own FDA labels.

    Cited source records

    Before
    dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098, journal-pmid-2229278, journal-pmid-34953531
    After
    dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098, journal-pmid-2229278, journal-pmid-34953531, fda-sandostatin-lar-label-2024, fda-mycapssa-label-2024

    Claim citations

    Before
    name: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; aliases: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; category: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; status: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098; summary: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; evidenceNote: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, journal-pmid-2229278, journal-pmid-34953531
    After
    name: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; aliases: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; category: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; status: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098; summary: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; evidenceNote: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-sandostatin-lar-label-2024, fda-mycapssa-label-2024, journal-pmid-2229278, journal-pmid-34953531
  6. Profile updated

    Petrelintide profile

    We added the published results of the ZUPREME 1 Phase 2 trial and two more ClinicalTrials.gov records. Earlier versions said the only published human results were from Phase 1 trials.

    PeptideScanner change date
    November 16, 2026
    Evidence lane
    Profile

    Evidence note

    Before
    The only published human results reviewed here are from two small randomized Phase 1 trials, which reported weight reductions. Phase 2 trials are listed as completed without results in the sources cited, and Phase 3 trials were recruiting in late 2026.
    After
    A published randomized, placebo-controlled Phase 2 trial in 485 adults with obesity (ZUPREME 1) reported average weight reductions of about 8% to 10% at 28 weeks, against about 2% with placebo; nausea was the most common side effect. Phase 3 trials were recruiting in late 2026.

    Cited source records

    Before
    ctg-nct07589686-v3, journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct06926842-2026-09-09-66566db76c0b, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d
    After
    ctg-nct07589686-v3, journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct06926842-2026-09-09-66566db76c0b, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d, journal-pmid-42810355, ctg-observation-nct07843498-2026-11-05-9b532d149aaf, ctg-observation-nct07076030-2026-01-28-68a10be352b4

    Claim citations

    Before
    name: ctg-nct07589686-v3; aliases: ctg-nct07589686-v3; category: ctg-nct07589686-v3; status: ctg-nct07589686-v3, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d; summary: ctg-nct07589686-v3, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b; evidenceNote: journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
    After
    name: ctg-nct07589686-v3; aliases: ctg-nct07589686-v3; category: ctg-nct07589686-v3; status: ctg-nct07589686-v3, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d; summary: ctg-nct07589686-v3, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b; evidenceNote: journal-pmid-42810355, journal-pmid-42017294, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
  7. Profile updated

    Selank profile

    We added a 2015 Russian clinical study of selank added to phenazepam in patients with anxiety disorders. Earlier versions said no human study was cited among the sources reviewed.

    PeptideScanner change date
    November 16, 2026
    Evidence lane
    Profile

    Evidence note

    Before
    No human study is cited in the reviewed sources; the published work cited here is in rats. No FDA approval is reported, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
    After
    The only human study found is a small 2015 Russian study of selank added to phenazepam in anxiety disorders, checkable only from its abstract; the other published work cited here is in rats. No FDA approval is reported, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.

    Cited source records

    Before
    fda-selank-identity, journal-pmid-28280289, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
    After
    fda-selank-identity, journal-pmid-28280289, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026, journal-pmid-26356395

    Claim citations

    Before
    name: fda-selank-identity, fda-bulk-peptide-risks; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-selank-identity, fda-bulk-peptide-risks; evidenceNote: journal-pmid-28280289, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
    After
    name: fda-selank-identity, fda-bulk-peptide-risks; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-selank-identity, fda-bulk-peptide-risks; evidenceNote: journal-pmid-26356395, journal-pmid-28280289, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
  8. Record updated

    ClinicalTrials.gov record NCT04775082

    ClinicalTrials.gov posted a newer version of NCT04775082, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    November 16, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was liraglutide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was liraglutide.

    Cited source date

    Before
    2026-07-09
    After
    2026-11-16

    Source observed date

    Before
    2026-08-10
    After
    2026-11-16

    Cited source records

    Before
    ctg-observation-nct04775082-2026-07-09-b565460c570f
    After
    ctg-observation-nct04775082-2026-07-09-b565460c570f-r2

    Headline citations

    Before
    ctg-observation-nct04775082-2026-07-09-b565460c570f
    After
    ctg-observation-nct04775082-2026-07-09-b565460c570f-r2

    Summary citations

    Before
    ctg-observation-nct04775082-2026-07-09-b565460c570f
    After
    ctg-observation-nct04775082-2026-07-09-b565460c570f-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was liraglutide. [sources: ctg-observation-nct04775082-2026-07-09-b565460c570f] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct04775082-2026-07-09-b565460c570f]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was liraglutide. [sources: ctg-observation-nct04775082-2026-07-09-b565460c570f-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct04775082-2026-07-09-b565460c570f-r2]

    Source snapshot commitment

    Before
    24552ee10aefc7c1245f029d4f1a81e678fa6746e5732b6ca15443b96475d446
    After
    5a2567b8b21c49bf22892d25aa2445244756f58c089059fc0f1d2d68b2007b4d
  9. Record updated

    ClinicalTrials.gov record NCT05278208

    ClinicalTrials.gov posted a newer version of NCT05278208, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    November 16, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

    Cited source date

    Before
    2026-07-20
    After
    2026-11-16

    Cited source records

    Before
    ctg-observation-nct05278208-2026-07-20-294c4af79959
    After
    ctg-observation-nct05278208-2026-07-20-294c4af79959-r2

    Headline citations

    Before
    ctg-observation-nct05278208-2026-07-20-294c4af79959
    After
    ctg-observation-nct05278208-2026-07-20-294c4af79959-r2

    Summary citations

    Before
    ctg-observation-nct05278208-2026-07-20-294c4af79959
    After
    ctg-observation-nct05278208-2026-07-20-294c4af79959-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959-r2]

    Source snapshot commitment

    Before
    27842e169ac0417a0d1e79de9ecf095381201b52a0342053ddcf98a7ea8d7793
    After
    caf11e90bc5b4e47237f7e29c972eafdab923d3b708553f0c1c65a7b25eae129
  10. Record updated

    ClinicalTrials.gov record NCT05669664

    ClinicalTrials.gov posted a newer version of NCT05669664, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    November 16, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was leuprolide.

    Cited source date

    Before
    2026-06-17
    After
    2026-11-16

    Source observed date

    Before
    2026-07-30
    After
    2026-11-16

    Cited source records

    Before
    ctg-observation-nct05669664-2026-06-17-1cc9e92daca2
    After
    ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2

    Headline citations

    Before
    ctg-observation-nct05669664-2026-06-17-1cc9e92daca2
    After
    ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2

    Summary citations

    Before
    ctg-observation-nct05669664-2026-06-17-1cc9e92daca2
    After
    ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was leuprolide. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2]

    Source snapshot commitment

    Before
    89e592b23c98d73045c9944adc28bbf5c628a3ebc7d2a85512423412fd1ca5c5
    After
    b3a5ff90419c4c0a50b967a4dcdb2433c975a8120c2f378701ac9c463645c350
  11. Record updated

    ClinicalTrials.gov record NCT06015893

    ClinicalTrials.gov posted a newer version of NCT06015893, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    November 16, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was semaglutide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide.

    Cited source date

    Before
    2026-08-03
    After
    2026-11-16

    Source observed date

    Before
    2026-08-13
    After
    2026-11-16

    Cited source records

    Before
    ctg-observation-nct06015893-2026-08-03-32ebc1c71794
    After
    ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2

    Headline citations

    Before
    ctg-observation-nct06015893-2026-08-03-32ebc1c71794
    After
    ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2

    Summary citations

    Before
    ctg-observation-nct06015893-2026-08-03-32ebc1c71794
    After
    ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2]

    Source snapshot commitment

    Before
    a4aeea2f9b0f59d39a847b4a9aeb5803154bc2def132f9465486d71eee198e5c
    After
    89b6fa98e2a99b1140238cec416d1f9a55fb79d619a93bb0413e7922c3bc223a
  12. Record updated

    ClinicalTrials.gov record NCT07220759

    ClinicalTrials.gov posted a newer version of NCT07220759, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    November 16, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-08-13T05:52:27.019Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was cagrilintide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was cagrilintide.

    Cited source date

    Before
    2026-08-03
    After
    2026-11-16

    Source observed date

    Before
    2026-08-13
    After
    2026-11-16

    Cited source records

    Before
    ctg-observation-nct07220759-2026-08-03-50fb10a6adbd
    After
    ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2

    Headline citations

    Before
    ctg-observation-nct07220759-2026-08-03-50fb10a6adbd
    After
    ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2

    Summary citations

    Before
    ctg-observation-nct07220759-2026-08-03-50fb10a6adbd
    After
    ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-08-13T05:52:27.019Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was cagrilintide. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was cagrilintide. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2]

    Source snapshot commitment

    Before
    25fdc0e1abb2c8ef471c57c54351ee7c4138fb59866fb3a21639ee2b2a876300
    After
    9223ed410ea30b6c045445fd7c2ca6ef3168ef01beef2c6fcaf1fa4c392ff10e
  13. Record updated

    ClinicalTrials.gov record NCT07843472

    ClinicalTrials.gov posted a newer version of NCT07843472, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    November 16, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was petrelintide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was petrelintide.

    Cited source date

    Before
    2026-10-07
    After
    2026-11-16

    Source observed date

    Before
    2026-11-14
    After
    2026-11-16

    Cited source records

    Before
    ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
    After
    ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2

    Headline citations

    Before
    ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
    After
    ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2

    Summary citations

    Before
    ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
    After
    ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was petrelintide. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was petrelintide. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2]

    Source snapshot commitment

    Before
    7839bde20c43885ca3c0ba78ceb7f2a639b702d6768d2a5fcdcf2a721f0540d4
    After
    26eb9ec866334a946792b0839f2306bcc8dfd707b971edc13ad9bf3520b3d5db
  14. Record updated

    Patient and caregiver experiences with a patient-support program for setmelanotide treatment of patients with Bardet-Biedl syndrome.

    PubMed revised the bibliographic metadata of PMID 40484968, with a metadata revision date of 2026-10-14. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    October 14, 2026
    Evidence lane
    Literature metadata

    Summary

    Before
    PubMed lists PMID 40484968 in Orphanet journal of rare diseases as Journal Article, with publication-date metadata of 2025-06-08 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
    After
    PubMed lists PMID 40484968 in Orphanet journal of rare diseases as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-06-08 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

    Cited source date

    Before
    2025-06-11
    After
    2026-10-14

    Source observed date

    Before
    2026-07-30
    After
    2026-11-16

    Cited source records

    Before
    pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99
    After
    pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99-r2

    Headline citations

    Before
    pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99
    After
    pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99-r2

    Summary citations

    Before
    pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99
    After
    pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99-r2

    Attributable context

    Before
    1. PubMed lists PMID 40484968 in Orphanet journal of rare diseases as Journal Article, with publication-date metadata of 2025-06-08 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99]
    After
    1. PubMed lists PMID 40484968 in Orphanet journal of rare diseases as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-06-08 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99-r2]

    Source snapshot commitment

    Before
    9b26f496b85118b02931ab1701b5b96b6376ccd66902857011505ee42468f951
    After
    3a6a88d99388c6145fbf4989900e2d739ed73e18a04045e4a51ee2b6730394ae
  15. Record updated

    Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students.

    PubMed revised the bibliographic metadata of PMID 42196730, with a metadata revision date of 2026-11-01. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    November 1, 2026
    Evidence lane
    Literature metadata

    Summary

    Before
    PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
    After
    PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

    Cited source date

    Before
    2026-07-17
    After
    2026-11-01

    Source observed date

    Before
    2026-08-10
    After
    2026-11-16

    Cited source records

    Before
    pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c
    After
    pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2

    Headline citations

    Before
    pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c
    After
    pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2

    Summary citations

    Before
    pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c
    After
    pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2

    Attributable context

    Before
    1. PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c]
    After
    1. PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2]

    Source snapshot commitment

    Before
    eab353679f205fa5faa1c057fdb6bd19f62c13d6b1d4c1142774b7af3956a42d
    After
    34b907ddc6cec008126f746b3c051e747e49a7b1a5d931a71ddab936a8fe30cd
  16. Record updated

    Dysregulated glucagon signaling contributes to hypoglycemia after vertical sleeve gastrectomy in mice.

    PubMed revised the bibliographic metadata of PMID 42270043, with a metadata revision date of 2026-10-28. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    October 28, 2026
    Evidence lane
    Literature metadata

    Summary

    Before
    PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
    After
    PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

    Cited source date

    Before
    2026-07-26
    After
    2026-10-28

    Source observed date

    Before
    2026-08-10
    After
    2026-11-16

    Cited source records

    Before
    pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38
    After
    pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38-r2

    Headline citations

    Before
    pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38
    After
    pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38-r2

    Summary citations

    Before
    pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38
    After
    pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38-r2

    Attributable context

    Before
    1. PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38]
    After
    1. PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38-r2]

    Source snapshot commitment

    Before
    2f489fa036a3bef3c01c415fdc534b027a76bb57092086428e59967706b46da0
    After
    7a40e26c7f83edcd1cf0060e963968f983e37478f69fbcbbcb1b5b2ff40ea51b
  17. Record updated

    Interlaboratory Comparison of a Glucagon and Oxyntomodulin Immuno-LC-MS/MS Assay: Implications for Diabetes Research.

    PubMed revised the bibliographic metadata of PMID 42400596, with a metadata revision date of 2026-11-04. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    November 4, 2026
    Evidence lane
    Literature metadata

    Summary

    Before
    PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, with publication-date metadata of 2026-07-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
    After
    PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, Comparative Study, with publication-date metadata of 2026-11-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

    Cited source date

    Before
    2026-07-04
    After
    2026-11-04

    Source observed date

    Before
    2026-08-10
    After
    2026-11-16

    Cited source records

    Before
    pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583
    After
    pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583-r2

    Headline citations

    Before
    pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583
    After
    pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583-r2

    Summary citations

    Before
    pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583
    After
    pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583-r2

    Attributable context

    Before
    1. PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, with publication-date metadata of 2026-07-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583]
    After
    1. PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, Comparative Study, with publication-date metadata of 2026-11-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583-r2]

    Source snapshot commitment

    Before
    4b3bd921a7d46c4b11998a3baec46da86d4c796af65645a749df5d3cebf50f50
    After
    1905f6b7c204dbbf7f742180be1de6d9b1634888554db65350b42f9cfaa2fa99
  18. Record updated

    Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report.

    PubMed revised the bibliographic metadata of PMID 42432542, with a metadata revision date of 2026-10-09. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    October 9, 2026
    Evidence lane
    Literature metadata

    Summary

    Before
    PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
    After
    PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, Case Reports, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

    Cited source date

    Before
    2026-07-10
    After
    2026-10-09

    Source observed date

    Before
    2026-08-10
    After
    2026-11-16

    Cited source records

    Before
    pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313
    After
    pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2

    Headline citations

    Before
    pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313
    After
    pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2

    Summary citations

    Before
    pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313
    After
    pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2

    Attributable context

    Before
    1. PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313]
    After
    1. PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, Case Reports, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2]

    Source snapshot commitment

    Before
    40371d4fc303f9890f165794e7bc1cdff3c5d283a74e058cd08dfec64e487e62
    After
    049db8537e8e0ed1acbba612a8b6e19e7a2b629ebe72c72ef6a452ac2b240137
  19. Record updated

    Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.

    PubMed revised the bibliographic metadata of PMID 42469146, with a metadata revision date of 2026-11-03. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    November 3, 2026
    Evidence lane
    Literature metadata

    Summary

    Before
    PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
    After
    PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, Review, Consensus Statement, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

    Cited source date

    Before
    2026-07-17
    After
    2026-11-03

    Source observed date

    Before
    2026-08-10
    After
    2026-11-16

    Cited source records

    Before
    pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55
    After
    pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2

    Headline citations

    Before
    pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55
    After
    pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2

    Summary citations

    Before
    pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55
    After
    pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2

    Attributable context

    Before
    1. PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55]
    After
    1. PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, Review, Consensus Statement, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2]

    Source snapshot commitment

    Before
    36da0f20323fce8e5f8e5d27c35090369921d8ad1f431ae9084ac66aa6ac558d
    After
    c20c2731770e88c463b15f02280c8ac57168fe802a51e0365364b5841872ef32
  20. Record updated

    Octreotide in the management of chyle leaks after head and neck surgery: a systematic review of cohort studies.

    PubMed revised the bibliographic metadata of PMID 42478204, with a metadata revision date of 2026-09-28. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    September 28, 2026
    Evidence lane
    Literature metadata

    Headline

    Before
    Octreotide in the Management of Chyle Leaks After Head and Neck Surgery: A Systematic Review of Cohort Studies.
    After
    Octreotide in the management of chyle leaks after head and neck surgery: a systematic review of cohort studies.

    Cited source date

    Before
    2026-07-21
    After
    2026-09-28

    Source observed date

    Before
    2026-08-10
    After
    2026-11-16

    Cited source records

    Before
    pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8
    After
    pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2

    Headline citations

    Before
    pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8
    After
    pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2

    Summary citations

    Before
    pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8
    After
    pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2

    Attributable context

    Before
    1. PubMed lists PMID 42478204 in The Journal of laryngology and otology as Journal Article, Review, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8]
    After
    1. PubMed lists PMID 42478204 in The Journal of laryngology and otology as Journal Article, Review, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2]

    Source snapshot commitment

    Before
    1f8596c0b9e8bff838b25afbc9a7de851b879199d537527522fe9f9d48ce30e3
    After
    4fc7c621f57d7585b4bc2b338a79fa715d8ad217dcab07615f4edf4b008613d0
  21. Record updated

    Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy.

    PubMed revised the bibliographic metadata of PMID 42708757, with a metadata revision date of 2026-09-11. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    September 11, 2026
    Evidence lane
    Literature metadata

    Summary

    Before
    PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
    After
    PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

    Cited source date

    Before
    2026-09-08
    After
    2026-09-11

    Source observed date

    Before
    2026-09-09
    After
    2026-11-16

    Cited source records

    Before
    pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c
    After
    pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2

    Headline citations

    Before
    pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c
    After
    pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2

    Summary citations

    Before
    pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c
    After
    pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2

    Attributable context

    Before
    1. PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c]
    After
    1. PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2]

    Source snapshot commitment

    Before
    23b3a5f532b67a12e51f3ef6a7bb92294cac365396be2f9b5b6ff93abe9ebffb
    After
    89e8c50a603c3bb0ebbd1568adb047cd59604e08d1ca3a08140875716f9a0371
  22. Record updated

    Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction.

    PubMed revised the bibliographic metadata of PMID 42709517, with a metadata revision date of 2026-10-30. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    October 30, 2026
    Evidence lane
    Literature metadata

    Headline

    Before
    Development of Chondroitin Sulfate ‑ Stabilized PLGA Microspheres of Exenatide via Polarity Gradient Extraction.
    After
    Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction.

    Summary

    Before
    PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
    After
    PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

    Cited source date

    Before
    2026-09-08
    After
    2026-10-30

    Source observed date

    Before
    2026-09-09
    After
    2026-11-16

    Cited source records

    Before
    pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e
    After
    pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2

    Headline citations

    Before
    pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e
    After
    pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2

    Summary citations

    Before
    pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e
    After
    pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2

    Attributable context

    Before
    1. PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e]
    After
    1. PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2]

    Source snapshot commitment

    Before
    5d05432049102feefa6ebeed4c8e4240ac757e1de40a7546110e89d12388d552
    After
    2d08bd01be3ecfa5274b4177f1b26c9df6241bdc2d9275560ce32844bffa91fe
  23. Record updated

    A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.

    PubMed revised the bibliographic metadata of PMID 42713641, with a metadata revision date of 2026-11-09. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 16, 2026
    Cited source date
    November 9, 2026
    Evidence lane
    Literature metadata

    Summary

    Before
    PubMed lists PMID 42713641 in NEJM evidence as Journal Article, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
    After
    PubMed lists PMID 42713641 in NEJM evidence as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

    Cited source date

    Before
    2026-09-09
    After
    2026-11-09

    Source observed date

    Before
    2026-09-09
    After
    2026-11-16

    Cited source records

    Before
    pubmed-observation-pmid-42713641-2026-09-09-3296b303c913
    After
    pubmed-observation-pmid-42713641-2026-09-09-3296b303c913-r2

    Headline citations

    Before
    pubmed-observation-pmid-42713641-2026-09-09-3296b303c913
    After
    pubmed-observation-pmid-42713641-2026-09-09-3296b303c913-r2

    Summary citations

    Before
    pubmed-observation-pmid-42713641-2026-09-09-3296b303c913
    After
    pubmed-observation-pmid-42713641-2026-09-09-3296b303c913-r2

    Attributable context

    Before
    1. PubMed lists PMID 42713641 in NEJM evidence as Journal Article, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42713641-2026-09-09-3296b303c913] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42713641-2026-09-09-3296b303c913]
    After
    1. PubMed lists PMID 42713641 in NEJM evidence as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42713641-2026-09-09-3296b303c913-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42713641-2026-09-09-3296b303c913-r2]

    Source snapshot commitment

    Before
    362b66e72d321a02130be7ccc7c20cd080741bd1e97c36106f63d64584349bd0
    After
    2fa248719f85b34615d923fa046cfed2db32537d3bf8c781c7d6a6846f844e57
  24. Profile updated

    Amycretin profile

    We added the six Novo Nordisk Phase 3 trials that ClinicalTrials.gov lists under the name zenagamtide, which the previous version did not describe, from registry records PeptideScanner retained on November 15, 2026.

    PeptideScanner change date
    November 15, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide. It is not FDA-approved.
    After
    An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide and in registered Phase 3 trials. It is not FDA-approved.

    Evidence note

    Before
    Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects.
    After
    Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects. Phase 3 trials registered as zenagamtide have not reported results.

    Cited source records

    Before
    ctg-nct06049329-v6, journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080
    After
    ctg-nct06049329-v6, journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080, ctg-observation-nct07668401-2026-08-24-5833a93b62ac, ctg-observation-nct07720271-2026-09-28-93ed8b5caeb7, ctg-observation-nct07797335-2026-09-01-bc9e4b3246b2, ctg-observation-nct07861100-2026-10-06-c1032ee418d6, ctg-observation-nct07931495-2026-11-12-23a664ffa2bf, ctg-observation-nct07931547-2026-11-12-2d2f13db63aa

    Claim citations

    Before
    name: ctg-nct06049329-v6; aliases: ctg-nct06049329-v6, journal-pmid-42532080; category: ctg-nct06049329-v6; status: ctg-nct06049329-v6, journal-pmid-42532080; summary: ctg-nct06049329-v6, journal-pmid-42532080; evidenceNote: journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080
    After
    name: ctg-nct06049329-v6; aliases: ctg-nct06049329-v6, journal-pmid-42532080; category: ctg-nct06049329-v6; status: ctg-nct06049329-v6, journal-pmid-42532080; summary: ctg-nct06049329-v6, journal-pmid-42532080, ctg-observation-nct07668401-2026-08-24-5833a93b62ac, ctg-observation-nct07720271-2026-09-28-93ed8b5caeb7, ctg-observation-nct07797335-2026-09-01-bc9e4b3246b2, ctg-observation-nct07861100-2026-10-06-c1032ee418d6, ctg-observation-nct07931495-2026-11-12-23a664ffa2bf, ctg-observation-nct07931547-2026-11-12-2d2f13db63aa; evidenceNote: journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080, ctg-observation-nct07668401-2026-08-24-5833a93b62ac, ctg-observation-nct07720271-2026-09-28-93ed8b5caeb7, ctg-observation-nct07797335-2026-09-01-bc9e4b3246b2, ctg-observation-nct07861100-2026-10-06-c1032ee418d6, ctg-observation-nct07931495-2026-11-12-23a664ffa2bf, ctg-observation-nct07931547-2026-11-12-2d2f13db63aa
  25. Profile updated

    Calcitonin salmon profile

    We added the name salmon calcitonin, which FDA’s substance registry lists for this ingredient, so that records using that name are matched. The label-based content did not change.

    PeptideScanner change date
    November 15, 2026
    Evidence lane
    Profile

    Related names

    Before
    Miacalcin
    After
    Miacalcin, Salmon calcitonin

    Cited source records

    Before
    dailymed-calcitonin-salmon-89cd4f46-b88a-4c10-b25c-47352280dc4e-v9, fda-application-nda017808
    After
    dailymed-calcitonin-salmon-89cd4f46-b88a-4c10-b25c-47352280dc4e-v9, fda-application-nda017808, fda-calcitonin-salmon-identity

    Claim citations

    Before
    name: dailymed-calcitonin-salmon-89cd4f46-b88a-4c10-b25c-47352280dc4e-v9; aliases: dailymed-calcitonin-salmon-89cd4f46-b88a-4c10-b25c-47352280dc4e-v9, fda-application-nda017808; category: dailymed-calcitonin-salmon-89cd4f46-b88a-4c10-b25c-47352280dc4e-v9; status: dailymed-calcitonin-salmon-89cd4f46-b88a-4c10-b25c-47352280dc4e-v9, fda-application-nda017808; summary: dailymed-calcitonin-salmon-89cd4f46-b88a-4c10-b25c-47352280dc4e-v9, fda-application-nda017808; evidenceNote: dailymed-calcitonin-salmon-89cd4f46-b88a-4c10-b25c-47352280dc4e-v9
    After
    name: dailymed-calcitonin-salmon-89cd4f46-b88a-4c10-b25c-47352280dc4e-v9; aliases: dailymed-calcitonin-salmon-89cd4f46-b88a-4c10-b25c-47352280dc4e-v9, fda-application-nda017808, fda-calcitonin-salmon-identity; category: dailymed-calcitonin-salmon-89cd4f46-b88a-4c10-b25c-47352280dc4e-v9; status: dailymed-calcitonin-salmon-89cd4f46-b88a-4c10-b25c-47352280dc4e-v9, fda-application-nda017808; summary: dailymed-calcitonin-salmon-89cd4f46-b88a-4c10-b25c-47352280dc4e-v9, fda-application-nda017808; evidenceNote: dailymed-calcitonin-salmon-89cd4f46-b88a-4c10-b25c-47352280dc4e-v9
  26. Profile updated

    Leuprolide profile

    We re-based this profile on the current Eligard label on DailyMed (SPL version 19, published May 11, 2026), because the generic label cited before is no longer marketed or served, and now describe the studies that label reports. HERO is described only as a trial in which leuprolide was the comparison treatment. Earlier versions remain available.

    PeptideScanner change date
    November 15, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A GnRH agonist FDA-approved since 1985 under several names. The cited label covers palliative treatment of advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.
    After
    A GnRH agonist FDA-approved since 1985 under several names. The cited Eligard label covers advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.

    Evidence note

    Before
    The label describes a controlled comparison with another hormone treatment in prostate cancer, and leuprolide served as the comparison treatment in a large randomized trial. Each leuprolide product has its own label and uses.
    After
    The cited Eligard label describes four open-label studies that measured testosterone suppression in men with prostate cancer. Each leuprolide product has its own label and uses.

    Cited source records

    Before
    dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda020263-1993-04-16-d5ec3f5822e0, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-drugs-nda213150-2020-05-01-40513bba6c48, fda-vobrig-approval-2026, journal-pmid-32469183
    After
    dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda020263-1993-04-16-d5ec3f5822e0, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-drugs-nda213150-2020-05-01-40513bba6c48, fda-vobrig-approval-2026, journal-pmid-32469183, fda-drugs-nda213225-2026-08-26-94e1fef9b739

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10]; U.S. Food and Drug Administration [sources: fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026]
    After
    U.S. National Library of Medicine [sources: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19]; U.S. Food and Drug Administration [sources: fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026]

    Claim citations

    Before
    name: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; aliases: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; category: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; status: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; summary: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026; evidenceNote: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, journal-pmid-32469183
    After
    name: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19; aliases: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; category: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19; status: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026, fda-drugs-nda213225-2026-08-26-94e1fef9b739; summary: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; evidenceNote: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19
  27. Profile updated

    Teriparatide profile

    We moved this profile to the current DailyMed label (SPL version 10, published September 21, 2026), which adds a separate warning about allergic reactions, and added the October 23, 2026 Drugs@FDA approval of a further generic teriparatide application. The previous version, citing label version 9, remains available.

    PeptideScanner change date
    November 15, 2026
    Evidence lane
    Profile

    Cited source records

    Before
    dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9, fda-drugs-nda021318-2002-11-26-2f4c2df07e0a, fda-drugs-nda211939-2019-10-04-4790820cc8d4, fda-drugs-anda211097-2023-11-16-2855aa79a2e2, fda-drugs-nda218771-2024-06-04-4293d16697eb
    After
    dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10, fda-drugs-nda021318-2002-11-26-2f4c2df07e0a, fda-drugs-nda211939-2019-10-04-4790820cc8d4, fda-drugs-anda211097-2023-11-16-2855aa79a2e2, fda-drugs-nda218771-2024-06-04-4293d16697eb, fda-drugs-anda214412-2026-10-23-57b5e048e2bf

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9]; U.S. Food and Drug Administration [sources: fda-drugs-nda021318-2002-11-26-2f4c2df07e0a]
    After
    U.S. National Library of Medicine [sources: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10]; U.S. Food and Drug Administration [sources: fda-drugs-nda021318-2002-11-26-2f4c2df07e0a]

    Claim citations

    Before
    name: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9; aliases: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9, fda-drugs-nda021318-2002-11-26-2f4c2df07e0a; category: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9; status: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9, fda-drugs-nda021318-2002-11-26-2f4c2df07e0a, fda-drugs-nda211939-2019-10-04-4790820cc8d4, fda-drugs-anda211097-2023-11-16-2855aa79a2e2, fda-drugs-nda218771-2024-06-04-4293d16697eb; summary: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9, fda-drugs-nda021318-2002-11-26-2f4c2df07e0a; evidenceNote: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9
    After
    name: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10; aliases: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10, fda-drugs-nda021318-2002-11-26-2f4c2df07e0a; category: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10; status: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10, fda-drugs-nda021318-2002-11-26-2f4c2df07e0a, fda-drugs-nda211939-2019-10-04-4790820cc8d4, fda-drugs-anda211097-2023-11-16-2855aa79a2e2, fda-drugs-nda218771-2024-06-04-4293d16697eb, fda-drugs-anda214412-2026-10-23-57b5e048e2bf; summary: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10, fda-drugs-nda021318-2002-11-26-2f4c2df07e0a; evidenceNote: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10
  28. Record updated

    ClinicalTrials.gov record NCT00569127

    ClinicalTrials.gov posted a newer version of NCT00569127, with a registry update date of 2026-11-13. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 13, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-08-10T18:10:03.946Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was octreotide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was octreotide.

    Cited source date

    Before
    2026-07-29
    After
    2026-11-13

    Source observed date

    Before
    2026-08-10
    After
    2026-11-15

    Cited source records

    Before
    ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6
    After
    ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2

    Headline citations

    Before
    ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6
    After
    ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2

    Summary citations

    Before
    ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6
    After
    ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-08-10T18:10:03.946Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was octreotide. [sources: ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was octreotide. [sources: ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2]

    Source snapshot commitment

    Before
    4390dd928958a7134ed3256e7f13b328aded4609af0716b640be601bdc7b0b49
    After
    e595e2f5fa81c1ca880e6d0f51234ea78337bb72b1db212f56a17026ff86feab
  29. Record updated

    ClinicalTrials.gov record NCT03150511

    ClinicalTrials.gov posted a newer version of NCT03150511, with a registry update date of 2026-11-09. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 9, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was tesamorelin.

    Cited source date

    Before
    2025-11-12
    After
    2026-11-09

    Source observed date

    Before
    2026-07-30
    After
    2026-11-15

    Cited source records

    Before
    ctg-observation-nct03150511-2025-11-12-65e14fe63370
    After
    ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2

    Headline citations

    Before
    ctg-observation-nct03150511-2025-11-12-65e14fe63370
    After
    ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2

    Summary citations

    Before
    ctg-observation-nct03150511-2025-11-12-65e14fe63370
    After
    ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin. [sources: ctg-observation-nct03150511-2025-11-12-65e14fe63370] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct03150511-2025-11-12-65e14fe63370]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was tesamorelin. [sources: ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2]

    Source snapshot commitment

    Before
    162498e56569aa7d626e3b59278dc3ecd3ba8322886eb40af608461e04ae085b
    After
    6580b5c21253335cfed5de2cdba5235532b58332c3edabaec07b275de27592e7
  30. Record updated

    ClinicalTrials.gov record NCT05093634

    ClinicalTrials.gov posted a newer version of NCT05093634, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 12, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT05093634 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was setmelanotide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT05093634 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was setmelanotide.

    Cited source date

    Before
    2026-08-06
    After
    2026-11-12

    Source observed date

    Before
    2026-08-13
    After
    2026-11-15

    Cited source records

    Before
    ctg-observation-nct05093634-2026-08-06-24ea1a709c92
    After
    ctg-observation-nct05093634-2026-08-06-24ea1a709c92-r2

    Headline citations

    Before
    ctg-observation-nct05093634-2026-08-06-24ea1a709c92
    After
    ctg-observation-nct05093634-2026-08-06-24ea1a709c92-r2

    Summary citations

    Before
    ctg-observation-nct05093634-2026-08-06-24ea1a709c92
    After
    ctg-observation-nct05093634-2026-08-06-24ea1a709c92-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT05093634 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was setmelanotide. [sources: ctg-observation-nct05093634-2026-08-06-24ea1a709c92] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05093634-2026-08-06-24ea1a709c92]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT05093634 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was setmelanotide. [sources: ctg-observation-nct05093634-2026-08-06-24ea1a709c92-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05093634-2026-08-06-24ea1a709c92-r2]

    Source snapshot commitment

    Before
    6fbef6067dbcb1bbee45d8a57b1b2988dc0209d75ea8be8aed8c748a3716a2f1
    After
    fd2f31677ba0e2dd0cf2d207f1bc59d37e80f4520eae373d790578b01a7d5c12
  31. Record updated

    ClinicalTrials.gov record NCT06077864

    ClinicalTrials.gov posted a newer version of NCT06077864, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 12, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-08-13T05:52:27.018Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was survodutide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.

    Cited source date

    Before
    2026-08-11
    After
    2026-11-12

    Source observed date

    Before
    2026-08-13
    After
    2026-11-15

    Cited source records

    Before
    ctg-observation-nct06077864-2026-08-11-60e24ca2b385
    After
    ctg-observation-nct06077864-2026-08-11-60e24ca2b385-r2

    Headline citations

    Before
    ctg-observation-nct06077864-2026-08-11-60e24ca2b385
    After
    ctg-observation-nct06077864-2026-08-11-60e24ca2b385-r2

    Summary citations

    Before
    ctg-observation-nct06077864-2026-08-11-60e24ca2b385
    After
    ctg-observation-nct06077864-2026-08-11-60e24ca2b385-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-08-13T05:52:27.018Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385-r2]

    Source snapshot commitment

    Before
    cf0165e7cc8a3abc8cc26353705836f72e2bfabb44e7e332c3453a3a99edeb3c
    After
    3b3fb4081c8a9faa0e6e6127299a5f54102ba28b220051200879395de0ee0e7d
  32. Record updated

    ClinicalTrials.gov record NCT06299098

    ClinicalTrials.gov posted a newer version of NCT06299098, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 12, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.

    Cited source date

    Before
    2026-07-21
    After
    2026-11-12

    Source observed date

    Before
    2026-08-10
    After
    2026-11-15

    Cited source records

    Before
    ctg-observation-nct06299098-2026-07-21-3f43d1be33b9
    After
    ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2

    Headline citations

    Before
    ctg-observation-nct06299098-2026-07-21-3f43d1be33b9
    After
    ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2

    Summary citations

    Before
    ctg-observation-nct06299098-2026-07-21-3f43d1be33b9
    After
    ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2]

    Source snapshot commitment

    Before
    5daab950986505011c46590a906c6633448e2a82fecd91776e83eb5058256666
    After
    ac8b8fbebfec0cf7c2103200aabff05341060cb529bf54ef4662b0b5175d3d73
  33. Record updated

    ClinicalTrials.gov record NCT06455059

    ClinicalTrials.gov posted a newer version of NCT06455059, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 12, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT06455059 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-20, and PeptideScanner's reviewed identity mapping was vosoritide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT06455059 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was vosoritide.

    Cited source date

    Before
    2026-01-20
    After
    2026-11-12

    Source observed date

    Before
    2026-07-30
    After
    2026-11-15

    Cited source records

    Before
    ctg-observation-nct06455059-2026-01-20-bc7bbe888685
    After
    ctg-observation-nct06455059-2026-01-20-bc7bbe888685-r2

    Headline citations

    Before
    ctg-observation-nct06455059-2026-01-20-bc7bbe888685
    After
    ctg-observation-nct06455059-2026-01-20-bc7bbe888685-r2

    Summary citations

    Before
    ctg-observation-nct06455059-2026-01-20-bc7bbe888685
    After
    ctg-observation-nct06455059-2026-01-20-bc7bbe888685-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT06455059 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-20, and PeptideScanner's reviewed identity mapping was vosoritide. [sources: ctg-observation-nct06455059-2026-01-20-bc7bbe888685] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06455059-2026-01-20-bc7bbe888685]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT06455059 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was vosoritide. [sources: ctg-observation-nct06455059-2026-01-20-bc7bbe888685-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06455059-2026-01-20-bc7bbe888685-r2]

    Source snapshot commitment

    Before
    c1a134540208b7c8559cbc8ed3b095213b97e583eb44ff6fd381e3a4f1d8772a
    After
    ff91dcd0672ce96a0e8ce77dd07de1a38c73643f2e2734fc60c686dbd64fca9c
  34. Record updated

    ClinicalTrials.gov record NCT06632457

    ClinicalTrials.gov posted a newer version of NCT06632457, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 12, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-08-13T05:52:27.009Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.

    Cited source date

    Before
    2026-08-10
    After
    2026-11-12

    Source observed date

    Before
    2026-08-13
    After
    2026-11-15

    Cited source records

    Before
    ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad
    After
    ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad-r2

    Headline citations

    Before
    ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad
    After
    ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad-r2

    Summary citations

    Before
    ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad
    After
    ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-08-13T05:52:27.009Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad-r2]

    Source snapshot commitment

    Before
    aa1782b5fe9710da04e66dfed333b0e6510ab67318e432efc980280dfbb568c7
    After
    36f98358c193a495d298a3a8445a8c403e3a74d6c2d792f4e84ed267e6736dfc
  35. Record updated

    ClinicalTrials.gov record NCT06772597

    ClinicalTrials.gov posted a newer version of NCT06772597, with a registry update date of 2026-11-13. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 13, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT06772597 at 2026-07-30T16:23:45.672Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was setmelanotide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT06772597 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was setmelanotide.

    Cited source date

    Before
    2026-02-12
    After
    2026-11-13

    Source observed date

    Before
    2026-07-30
    After
    2026-11-15

    Cited source records

    Before
    ctg-observation-nct06772597-2026-02-12-ba49a51071c7
    After
    ctg-observation-nct06772597-2026-02-12-ba49a51071c7-r2

    Headline citations

    Before
    ctg-observation-nct06772597-2026-02-12-ba49a51071c7
    After
    ctg-observation-nct06772597-2026-02-12-ba49a51071c7-r2

    Summary citations

    Before
    ctg-observation-nct06772597-2026-02-12-ba49a51071c7
    After
    ctg-observation-nct06772597-2026-02-12-ba49a51071c7-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT06772597 at 2026-07-30T16:23:45.672Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was setmelanotide. [sources: ctg-observation-nct06772597-2026-02-12-ba49a51071c7] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06772597-2026-02-12-ba49a51071c7]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT06772597 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was setmelanotide. [sources: ctg-observation-nct06772597-2026-02-12-ba49a51071c7-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06772597-2026-02-12-ba49a51071c7-r2]

    Source snapshot commitment

    Before
    66179831a9e49f0dfcb58fc735a6021a37852bed46a7705a89b28ef5cc420300
    After
    53845d716856a226e5d438cceaf34833245c5dcfdf1828ef967ca8ce5a8bbd66
  36. Record updated

    ClinicalTrials.gov record NCT07463846

    ClinicalTrials.gov posted a newer version of NCT07463846, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 12, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

    Cited source date

    Before
    2026-08-12
    After
    2026-11-12

    Source observed date

    Before
    2026-08-13
    After
    2026-11-15

    Cited source records

    Before
    ctg-observation-nct07463846-2026-08-12-3a462c76c655
    After
    ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2

    Headline citations

    Before
    ctg-observation-nct07463846-2026-08-12-3a462c76c655
    After
    ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2

    Summary citations

    Before
    ctg-observation-nct07463846-2026-08-12-3a462c76c655
    After
    ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2]

    Source snapshot commitment

    Before
    6ae7bcba9aa2922ec5cb26cb9ce412469fb389b44aa70fa29776d480876bf7e7
    After
    419d66b2ad3451743220da2eef392971ff3a949579c07dc08771fc73c36e6ac5
  37. Record updated

    ClinicalTrials.gov record NCT07481734

    ClinicalTrials.gov posted a newer version of NCT07481734, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 12, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was tesamorelin.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin.

    Cited source date

    Before
    2026-03-19
    After
    2026-11-12

    Source observed date

    Before
    2026-07-30
    After
    2026-11-15

    Cited source records

    Before
    ctg-observation-nct07481734-2026-03-19-79e26d9bce31
    After
    ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2

    Headline citations

    Before
    ctg-observation-nct07481734-2026-03-19-79e26d9bce31
    After
    ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2

    Summary citations

    Before
    ctg-observation-nct07481734-2026-03-19-79e26d9bce31
    After
    ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was tesamorelin. [sources: ctg-observation-nct07481734-2026-03-19-79e26d9bce31] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07481734-2026-03-19-79e26d9bce31]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin. [sources: ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2]

    Source snapshot commitment

    Before
    71841b0389a60f9ef68bd50fb31e7127ae4fa8dd080a1e8c83ffdbfea0383622
    After
    4db6e7df5bfe3f74593f4acab120fc16eae461271e7bd5c4ae9e1a305979d20d
  38. Record updated

    ClinicalTrials.gov record NCT07487363

    ClinicalTrials.gov posted a newer version of NCT07487363, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 12, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was tb-500.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tb-500.

    Cited source date

    Before
    2026-03-23
    After
    2026-11-12

    Source observed date

    Before
    2026-07-30
    After
    2026-11-15

    Cited source records

    Before
    ctg-observation-nct07487363-2026-03-23-eb4b60623fcf
    After
    ctg-observation-nct07487363-2026-03-23-eb4b60623fcf-r2

    Headline citations

    Before
    ctg-observation-nct07487363-2026-03-23-eb4b60623fcf
    After
    ctg-observation-nct07487363-2026-03-23-eb4b60623fcf-r2

    Summary citations

    Before
    ctg-observation-nct07487363-2026-03-23-eb4b60623fcf
    After
    ctg-observation-nct07487363-2026-03-23-eb4b60623fcf-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was tb-500. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tb-500. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf-r2]

    Source snapshot commitment

    Before
    d7340d8da0bedde68aaaca06505e04d72aa1c49971d4f34e584ac543e56c8ed6
    After
    dee9c9d5083b9463d9b874710e1cfe524293c68c31954d4c2e5d9f1276bf9827
  39. Record updated

    ClinicalTrials.gov record NCT07531251

    ClinicalTrials.gov posted a newer version of NCT07531251, with a registry update date of 2026-11-09. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 9, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was elamipretide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was elamipretide.

    Cited source date

    Before
    2026-07-13
    After
    2026-11-09

    Source observed date

    Before
    2026-08-10
    After
    2026-11-15

    Cited source records

    Before
    ctg-observation-nct07531251-2026-07-13-a3abd3798f6f
    After
    ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2

    Headline citations

    Before
    ctg-observation-nct07531251-2026-07-13-a3abd3798f6f
    After
    ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2

    Summary citations

    Before
    ctg-observation-nct07531251-2026-07-13-a3abd3798f6f
    After
    ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was elamipretide. [sources: ctg-observation-nct07531251-2026-07-13-a3abd3798f6f] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07531251-2026-07-13-a3abd3798f6f]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was elamipretide. [sources: ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2]

    Source snapshot commitment

    Before
    cd18ee2b24e957403e6fb8e09ac12d4bfc61572774f57546d541ffda74c3fb1f
    After
    b1b09dfd129e96bca737737861669ba793549d2ec86352284d46bfaf2b7b5c0d
  40. Record updated

    ClinicalTrials.gov record NCT07734792

    ClinicalTrials.gov posted a newer version of NCT07734792, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 12, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was tirzepatide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

    Cited source date

    Before
    2026-07-29
    After
    2026-11-12

    Source observed date

    Before
    2026-08-10
    After
    2026-11-15

    Cited source records

    Before
    ctg-observation-nct07734792-2026-07-29-16e12449ec7c
    After
    ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2

    Headline citations

    Before
    ctg-observation-nct07734792-2026-07-29-16e12449ec7c
    After
    ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2

    Summary citations

    Before
    ctg-observation-nct07734792-2026-07-29-16e12449ec7c
    After
    ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2]

    Source snapshot commitment

    Before
    e48a94be6cabaa41355f8224bd8766914e7dba01f18d17df87aba2ad5484b22a
    After
    4bc75d2c3256725d011167df3f4a7d859b4c36321408b50414bc7c7cf8b0623d
  41. Record updated

    ClinicalTrials.gov record NCT07754461

    ClinicalTrials.gov posted a newer version of NCT07754461, with a registry update date of 2026-11-13. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 13, 2026
    Evidence lane
    Clinical trials

    Summary

    Before
    PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
    After
    PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was survodutide.

    Cited source date

    Before
    2026-08-10
    After
    2026-11-13

    Source observed date

    Before
    2026-08-13
    After
    2026-11-15

    Cited source records

    Before
    ctg-observation-nct07754461-2026-08-10-d71d6065261a
    After
    ctg-observation-nct07754461-2026-08-10-d71d6065261a-r2

    Headline citations

    Before
    ctg-observation-nct07754461-2026-08-10-d71d6065261a
    After
    ctg-observation-nct07754461-2026-08-10-d71d6065261a-r2

    Summary citations

    Before
    ctg-observation-nct07754461-2026-08-10-d71d6065261a
    After
    ctg-observation-nct07754461-2026-08-10-d71d6065261a-r2

    Attributable context

    Before
    1. PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a]
    After
    1. PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a-r2]

    Source snapshot commitment

    Before
    b25f4b8af47d59c50496bb719a2c3a947d387fcfbb4510d57581439523e347d9
    After
    7ee0a3130e4e3b5a7e1ab7330f46659e395d21c4aa5ceb3790c632874e57efef
  42. Profile status changed

    Abaloparatide profile

    We added a plain-language reader guide with cited answers, re-checked the Tymlos label, and added the Drugs@FDA approval record.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Tymlos for osteoporosis

    Profile summary

    Before
    A parathyroid hormone-related peptide analogue. This profile cites a U.S. label record.
    After
    A PTHrP analogue approved by FDA as Tymlos for postmenopausal women with osteoporosis at high risk of fracture and to increase bone density in men with osteoporosis.

    Evidence note

    Before
    The cited DailyMed label identifies Abaloparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    A large randomized, placebo-controlled trial described in the label found fewer new spine fractures than placebo. The label states that abaloparatide caused osteosarcoma in rats and that it is unknown whether it does so in humans.

    Cited source records

    Before
    dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19
    After
    dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19, fda-drugs-nda208743-2017-04-28-566de3ccde8d

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19]
    After
    U.S. National Library of Medicine [sources: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19]; U.S. Food and Drug Administration [sources: fda-drugs-nda208743-2017-04-28-566de3ccde8d]

    Claim citations

    Before
    name: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; aliases: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; category: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; status: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; summary: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; evidenceNote: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19
    After
    name: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; aliases: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; category: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19; status: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19, fda-drugs-nda208743-2017-04-28-566de3ccde8d; summary: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19, fda-drugs-nda208743-2017-04-28-566de3ccde8d; evidenceNote: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19
  43. Profile status changed

    Afamelanotide profile

    We added a plain-language reader guide with cited answers, re-checked the Scenesse label, and added the Drugs@FDA approval record.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Scenesse for erythropoietic protoporphyria

    Profile summary

    Before
    A melanocortin analogue. This profile cites a U.S. label record.
    After
    A melanocortin receptor agonist approved by FDA as Scenesse to increase pain-free light exposure in adults with erythropoietic protoporphyria.

    Evidence note

    Before
    The cited DailyMed label identifies Afamelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    Two smaller randomized, vehicle-controlled trials described in the label found more time in direct sunlight on pain-free days than with the vehicle. The label warns of serious allergic reactions and darkening of skin, moles and freckles.

    Cited source records

    Before
    dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11
    After
    dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11, fda-drugs-nda210797-2019-10-08-afc1f17d523d

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11]
    After
    U.S. National Library of Medicine [sources: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11]; U.S. Food and Drug Administration [sources: fda-drugs-nda210797-2019-10-08-afc1f17d523d]

    Claim citations

    Before
    name: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11; aliases: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11; category: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11; status: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11; summary: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11; evidenceNote: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11
    After
    name: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11; aliases: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11; category: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11; status: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11, fda-drugs-nda210797-2019-10-08-afc1f17d523d; summary: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11, fda-drugs-nda210797-2019-10-08-afc1f17d523d; evidenceNote: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11
  44. Profile status changed

    Amycretin profile

    We added a plain-language reader guide with cited answers, published trial results from our human evidence review, and the 2026 report that renames amycretin zenagamtide.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    Investigational
    After
    In clinical trials; not FDA-approved

    Profile summary

    Before
    An amylin and GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.
    After
    An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide. It is not FDA-approved.

    Evidence note

    Before
    ClinicalTrials.gov lists a Novo Nordisk oral amycretin study as completed, last updated March 5, 2025.
    After
    Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects.

    Related names

    Before
    None recorded
    After
    Zenagamtide

    Cited source records

    Before
    ctg-nct06049329-v6
    After
    ctg-nct06049329-v6, journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080

    Claim citations

    Before
    name: ctg-nct06049329-v6; aliases: ctg-nct06049329-v6; category: ctg-nct06049329-v6; status: ctg-nct06049329-v6; summary: ctg-nct06049329-v6; evidenceNote: ctg-nct06049329-v6
    After
    name: ctg-nct06049329-v6; aliases: ctg-nct06049329-v6, journal-pmid-42532080; category: ctg-nct06049329-v6; status: ctg-nct06049329-v6, journal-pmid-42532080; summary: ctg-nct06049329-v6, journal-pmid-42532080; evidenceNote: journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080
  45. Profile status changed

    Bremelanotide profile

    We added a plain-language reader guide with cited answers, re-checked the Vyleesi label, and added the Drugs@FDA approval record and FDA’s October 22, 2026 approval of a labeling supplement.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Vyleesi for HSDD in premenopausal women

    Profile summary

    Before
    A melanocortin receptor agonist peptide. This profile cites a U.S. label record.
    After
    A melanocortin receptor agonist approved by FDA as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women.

    Evidence note

    Before
    The cited DailyMed label identifies Bremelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    Two large randomized trials described in the label found small improvements in desire and distress scores but no difference in satisfying sexual events. The label states that it is contraindicated in uncontrolled high blood pressure or known cardiovascular disease.

    Cited source records

    Before
    dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1, fda-bremelanotide-identity
    After
    dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1, fda-bremelanotide-identity, fda-drugs-nda210557-2019-06-21-d4c7e45d4a54, fda-vyleesi-s005-approval-2026

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1]
    After
    U.S. National Library of Medicine [sources: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1]; U.S. Food and Drug Administration [sources: fda-drugs-nda210557-2019-06-21-d4c7e45d4a54]

    Claim citations

    Before
    name: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; aliases: fda-bremelanotide-identity; category: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; status: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; summary: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; evidenceNote: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1
    After
    name: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; aliases: fda-bremelanotide-identity; category: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; status: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1, fda-drugs-nda210557-2019-06-21-d4c7e45d4a54; summary: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1, fda-drugs-nda210557-2019-06-21-d4c7e45d4a54; evidenceNote: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1
  46. Profile status changed

    Cagrilintide profile

    We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which states that cagrilintide cannot be used in compounding.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    Investigational
    After
    In clinical trials; not FDA-approved

    Profile summary

    Before
    A long-acting amylin analogue under study. This profile cites a recruiting ClinicalTrials.gov record.
    After
    An experimental long-acting amylin analogue from Novo Nordisk, studied alone and combined with semaglutide as CagriSema. FDA says it is not an approved drug and cannot be used in compounding.

    Evidence note

    Before
    ClinicalTrials.gov lists a Novo Nordisk pediatric study as recruiting, updated July 17, 2026.
    After
    A published Phase 2 trial of cagrilintide alone and large Phase 3 trials of the cagrilintide-semaglutide combination report weight loss; combination results cannot be credited to cagrilintide alone. FDA states that cagrilintide has not been found safe and effective for any condition.

    Related names

    Before
    AM833
    After
    AM833, CagriSema

    Cited source records

    Before
    ctg-nct07253285-v5
    After
    ctg-nct07253285-v5, fda-unapproved-glp1-concerns-2026-r2, journal-pmid-34798060, journal-pmid-40544433, ctg-observation-nct07220759-2026-08-03-50fb10a6adbd, ctg-observation-nct07745504-2026-08-04-624035118e08

    Named organizations

    Before
    Novo Nordisk A/S [sources: ctg-nct07253285-v5]
    After
    Novo Nordisk A/S [sources: ctg-nct07253285-v5]; U.S. Food and Drug Administration [sources: fda-unapproved-glp1-concerns-2026-r2]

    Claim citations

    Before
    name: ctg-nct07253285-v5; aliases: ctg-nct07253285-v5; category: ctg-nct07253285-v5; status: ctg-nct07253285-v5; summary: ctg-nct07253285-v5; evidenceNote: ctg-nct07253285-v5
    After
    name: ctg-nct07253285-v5; aliases: ctg-nct07253285-v5, journal-pmid-40544433; category: ctg-nct07253285-v5; status: ctg-nct07253285-v5, ctg-observation-nct07220759-2026-08-03-50fb10a6adbd, fda-unapproved-glp1-concerns-2026-r2; summary: journal-pmid-34798060, journal-pmid-40544433, fda-unapproved-glp1-concerns-2026-r2; evidenceNote: journal-pmid-34798060, journal-pmid-40544433, fda-unapproved-glp1-concerns-2026-r2
  47. Profile status changed

    Dulaglutide profile

    We added a plain-language reader guide with cited answers, re-checked the Trulicity label, and added the Drugs@FDA approval record.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Trulicity

    Profile summary

    Before
    A GLP-1 receptor agonist. This profile cites a Trulicity label.
    After
    A GLP-1 receptor agonist approved by FDA as Trulicity for blood-sugar control in type 2 diabetes and to lower cardiovascular risk in certain adults with type 2 diabetes.

    Evidence note

    Before
    The cited DailyMed label identifies Dulaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    Large randomized trials described in the label support its uses, including a cardiovascular outcomes trial of 9,901 adults. The label carries a boxed warning about thyroid C-cell tumors in rats.

    Cited source records

    Before
    dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62
    After
    dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62, fda-drugs-bla125469-2014-09-18-c02325f3972c

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62]
    After
    U.S. National Library of Medicine [sources: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62]; U.S. Food and Drug Administration [sources: fda-drugs-bla125469-2014-09-18-c02325f3972c]

    Claim citations

    Before
    name: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62; aliases: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62; category: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62; status: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62; summary: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62; evidenceNote: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62
    After
    name: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62; aliases: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62; category: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62; status: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62, fda-drugs-bla125469-2014-09-18-c02325f3972c; summary: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62, fda-drugs-bla125469-2014-09-18-c02325f3972c; evidenceNote: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62
  48. Profile status changed

    Elamipretide profile

    We added a plain-language reader guide with cited answers drawn from the Forzinity prescribing information and FDA’s accelerated approval letter, and added the Federal Register notice of the 2024 advisory committee meeting.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. accelerated approval for a specified Barth syndrome population
    After
    FDA-approved as Forzinity under accelerated approval for Barth syndrome

    Profile summary

    Before
    FDA granted Forzinity (elamipretide) accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.
    After
    A mitochondria-targeting peptide that FDA granted accelerated approval as Forzinity to improve muscle strength in people with Barth syndrome weighing at least 30 kg.

    Evidence note

    Before
    FDA's September 19, 2025 approval letter requires a confirmatory trial to verify clinical benefit. The approval concerns this product and specified use; a recruiting trial record does not describe its full regulatory status.
    After
    The approval rests on muscle-strength increases seen in the open-label extension of a 12-person trial that missed its main goals. FDA requires a randomized confirmatory trial and may withdraw the approval if benefit is not verified.

    Cited source records

    Before
    ctg-nct07531251-v4, fda-forzinity-approval-2025, fda-forzinity-label-2025
    After
    ctg-nct07531251-v4, fda-forzinity-approval-2025, fda-forzinity-label-2025, federal-register-2024-20062-66035b025ae4

    Named organizations

    Before
    Stealth BioTherapeutics Inc. [sources: ctg-nct07531251-v4]
    After
    Stealth BioTherapeutics Inc. [sources: ctg-nct07531251-v4]; U.S. Food and Drug Administration [sources: fda-forzinity-approval-2025]

    Claim citations

    Before
    name: ctg-nct07531251-v4; aliases: ctg-nct07531251-v4, fda-forzinity-approval-2025; category: ctg-nct07531251-v4; status: fda-forzinity-approval-2025; summary: fda-forzinity-approval-2025; evidenceNote: fda-forzinity-approval-2025
    After
    name: ctg-nct07531251-v4; aliases: ctg-nct07531251-v4, fda-forzinity-approval-2025; category: ctg-nct07531251-v4; status: fda-forzinity-approval-2025, fda-forzinity-label-2025; summary: fda-forzinity-approval-2025, fda-forzinity-label-2025; evidenceNote: fda-forzinity-label-2025, fda-forzinity-approval-2025
  49. Profile status changed

    Epitalon profile

    We added a plain-language reader guide with cited answers, re-checked FDA’s epitalon briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists epitalon acetate. FDA has not issued a final 503A rule.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    FDA compounding assessment in the cited records
    After
    Not an FDA-approved drug

    Profile summary

    Before
    A synthetic tetrapeptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.
    After
    A synthetic four-amino-acid peptide that is not FDA-approved. FDA’s 2026 review found only a few small human reports and no studies in people with insomnia.

    Evidence note

    Before
    FDA's July 2026 briefing evaluates epitalon free base and acetate and distinguishes the tetrapeptide from epithalamin, a pineal-gland extract. The briefing is an advisory-process assessment, not a final regulatory determination.
    After
    FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists epitalon acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make epitalon an FDA-approved drug.

    Related names

    Before
    AEDG, Epithalon
    After
    AEDG, Epithalon, Ala-Glu-Asp-Gly

    Cited source records

    Before
    fda-epitalon-briefing, fda-pcac-peptide-meeting-2026
    After
    fda-epitalon-briefing, fda-pcac-peptide-meeting-2026, fda-bulk-peptide-risks, federal-register-2026-07361-0aed508462b2, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026

    Named organizations

    Before
    U.S. Food and Drug Administration [sources: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026]
    After
    U.S. Food and Drug Administration [sources: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]

    Claim citations

    Before
    name: fda-epitalon-briefing; aliases: fda-epitalon-briefing; category: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026; status: fda-epitalon-briefing; summary: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-epitalon-briefing
    After
    name: fda-epitalon-briefing; aliases: fda-epitalon-briefing; category: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026; status: fda-epitalon-briefing; summary: fda-epitalon-briefing; evidenceNote: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
  50. Profile status changed

    Exenatide profile

    We added a plain-language reader guide with cited answers, re-checked the generic exenatide label, added the Drugs@FDA approval records and the EXSCEL outcomes trial, and added FDA’s November 13, 2026 determination that Byetta was not withdrawn from sale for safety or effectiveness reasons.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Byetta, Bydureon and generic exenatide

    Profile summary

    Before
    A GLP-1 receptor agonist. This profile cites a U.S. label record.
    After
    A GLP-1 receptor agonist first approved by FDA as Byetta in 2005 to improve blood-sugar control in adults with type 2 diabetes.

    Evidence note

    Before
    The cited DailyMed label identifies Exenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    Randomized trials described in the label show lower HbA1c than placebo. A large outcomes trial of a longer-acting exenatide product did not show a reduction in cardiovascular events. In November 2026 FDA determined that Byetta was not withdrawn from sale for safety or effectiveness reasons.

    Related names

    Before
    None recorded
    After
    Byetta, Bydureon

    Cited source records

    Before
    dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17
    After
    dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17, fda-drugs-nda021773-2005-04-28-80405b2e0c23, fda-drugs-nda022200-2012-01-27-454d1777c87f, fda-drugs-nda209210-2017-10-20-473b81562789, fda-drugs-anda206697-2024-11-19-5725057d6a94, federal-register-2026-23141-024f888bd7b4, journal-pmid-28910237

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17]
    After
    U.S. National Library of Medicine [sources: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17]; U.S. Food and Drug Administration [sources: fda-drugs-nda021773-2005-04-28-80405b2e0c23, federal-register-2026-23141-024f888bd7b4]

    Claim citations

    Before
    name: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17; aliases: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17; category: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17; status: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17; summary: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17; evidenceNote: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17
    After
    name: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17; aliases: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17, fda-drugs-nda021773-2005-04-28-80405b2e0c23, fda-drugs-nda022200-2012-01-27-454d1777c87f; category: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17; status: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17, fda-drugs-nda021773-2005-04-28-80405b2e0c23, fda-drugs-nda022200-2012-01-27-454d1777c87f, fda-drugs-nda209210-2017-10-20-473b81562789, fda-drugs-anda206697-2024-11-19-5725057d6a94; summary: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17, fda-drugs-nda021773-2005-04-28-80405b2e0c23; evidenceNote: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17, journal-pmid-28910237, federal-register-2026-23141-024f888bd7b4
  51. Profile status changed

    Glucagon profile

    We added a plain-language reader guide with cited answers, re-checked the Gvoke and Gvoke VialDx label, and added Drugs@FDA approval records for glucagon products.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Gvoke, Baqsimi and other glucagon products

    Profile summary

    Before
    A peptide hormone. The cited U.S. label distinguishes Gvoke for severe hypoglycemia from Gvoke VialDx for diagnostic use.
    After
    A peptide hormone that raises blood sugar, FDA-approved since 1960. The cited label covers Gvoke for severe low blood sugar and Gvoke VialDx as a diagnostic aid.

    Evidence note

    Before
    The cited label describes subcutaneous Gvoke for severe hypoglycemia in people with diabetes aged two years and older, and intravenous Gvoke VialDx as a diagnostic aid in adults. The product, route and indication must remain distinct.
    After
    Smaller controlled crossover studies described in the label found that nearly all participants reached the target rise in blood sugar within 30 minutes. The label keeps the severe-hypoglycemia and diagnostic uses separate.

    Related names

    Before
    Gvoke VialDx
    After
    Gvoke VialDx, Gvoke, Baqsimi

    Cited source records

    Before
    dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2
    After
    dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2, fda-drugs-nda012122-1960-11-14-3232418447c3, fda-drugs-nda201849-2015-05-08-7be1ec311130, fda-drugs-nda210134-2019-07-24-69c8d7c9e55f, fda-drugs-nda212097-2019-09-10-289a38c344bd

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2]
    After
    U.S. National Library of Medicine [sources: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2]; U.S. Food and Drug Administration [sources: fda-drugs-nda212097-2019-09-10-289a38c344bd]

    Claim citations

    Before
    name: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2; aliases: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2; category: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2; status: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2; summary: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2; evidenceNote: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2
    After
    name: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2; aliases: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2, fda-drugs-nda212097-2019-09-10-289a38c344bd, fda-drugs-nda210134-2019-07-24-69c8d7c9e55f; category: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2; status: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2, fda-drugs-nda012122-1960-11-14-3232418447c3, fda-drugs-nda210134-2019-07-24-69c8d7c9e55f, fda-drugs-nda212097-2019-09-10-289a38c344bd; summary: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2, fda-drugs-nda012122-1960-11-14-3232418447c3; evidenceNote: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2
  52. Profile status changed

    Insulin glargine-aldy profile

    We added a plain-language reader guide with cited answers, re-checked the Langlara label, and added the Drugs@FDA record and FDA’s April 2026 approval letter.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Langlara

    Profile summary

    Before
    A long-acting insulin analogue. This profile cites a U.S. prescription label.
    After
    A long-acting insulin glargine product licensed by FDA as Langlara in April 2026 to improve blood-sugar control in adults and children with diabetes.

    Evidence note

    Before
    The cited DailyMed label identifies Insulin glargine-aldy and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    FDA’s approval letter describes the application as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus. The clinical studies in the label are insulin glargine studies against NPH insulin, not trials of insulin glargine-aldy itself.

    Cited source records

    Before
    dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5
    After
    dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5]
    After
    U.S. National Library of Medicine [sources: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5]; U.S. Food and Drug Administration [sources: fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026]

    Claim citations

    Before
    name: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; aliases: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; category: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; status: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; summary: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; evidenceNote: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5
    After
    name: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; aliases: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; category: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; status: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; summary: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; evidenceNote: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-langlara-approval-2026
  53. Profile status changed

    KPV profile

    We added a plain-language reader guide with cited answers, re-checked FDA’s KPV briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists KPV acetate. FDA has not issued a final 503A rule.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    FDA compounding assessment in the cited records
    After
    Not an FDA-approved drug

    Profile summary

    Before
    A tripeptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.
    After
    A three-amino-acid peptide that is not FDA-approved. FDA’s 2026 review found no studies of KPV in people.

    Evidence note

    Before
    FDA's July 2026 briefing evaluates KPV-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
    After
    FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists KPV acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make KPV an FDA-approved drug.

    Cited source records

    Before
    fda-kpv-briefing, fda-pcac-peptide-meeting-2026
    After
    fda-kpv-briefing, fda-pcac-peptide-meeting-2026, fda-bulk-peptide-risks, federal-register-2026-07361-0aed508462b2, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026

    Named organizations

    Before
    U.S. Food and Drug Administration [sources: fda-kpv-briefing, fda-pcac-peptide-meeting-2026]
    After
    U.S. Food and Drug Administration [sources: fda-kpv-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]

    Claim citations

    Before
    name: fda-kpv-briefing; aliases: fda-kpv-briefing; category: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; status: fda-kpv-briefing; summary: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-kpv-briefing
    After
    name: fda-kpv-briefing; aliases: fda-kpv-briefing; category: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; status: fda-kpv-briefing; summary: fda-kpv-briefing; evidenceNote: fda-kpv-briefing, fda-pcac-peptide-meeting-2026, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
  54. Profile status changed

    Lanreotide profile

    We added a plain-language reader guide with cited answers, re-checked the generic lanreotide label, and added Drugs@FDA approval records for lanreotide products.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Somatuline Depot and other lanreotide products

    Profile summary

    Before
    A somatostatin analogue. This profile cites a U.S. label record.
    After
    A somatostatin analogue first approved by FDA as Somatuline Depot in 2007. The cited label covers acromegaly, certain neuroendocrine tumors and carcinoid syndrome.

    Evidence note

    Before
    The cited DailyMed label identifies Lanreotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    Smaller randomized, placebo-controlled trials described in the label support its uses, including a tumor trial in which lanreotide lengthened progression-free survival. The cited label has no boxed warning.

    Related names

    Before
    Lanreotide acetate
    After
    Lanreotide acetate, Somatuline Depot

    Cited source records

    Before
    dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3
    After
    dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3, fda-drugs-nda022074-2007-08-30-439ff00e36be, fda-drugs-nda215395-2021-12-17-2de401fe75fc, fda-drugs-anda217193-2024-05-21-688e02d085c4

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3]
    After
    U.S. National Library of Medicine [sources: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3]; U.S. Food and Drug Administration [sources: fda-drugs-nda022074-2007-08-30-439ff00e36be]

    Claim citations

    Before
    name: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3; aliases: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3; category: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3; status: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3; summary: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3; evidenceNote: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3
    After
    name: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3; aliases: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3, fda-drugs-nda022074-2007-08-30-439ff00e36be; category: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3; status: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3, fda-drugs-nda022074-2007-08-30-439ff00e36be, fda-drugs-nda215395-2021-12-17-2de401fe75fc, fda-drugs-anda217193-2024-05-21-688e02d085c4; summary: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3, fda-drugs-nda022074-2007-08-30-439ff00e36be; evidenceNote: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3
  55. Profile status changed

    Leuprolide profile

    We added a plain-language reader guide with cited answers, Drugs@FDA approval records for leuprolide products, FDA’s August 26, 2026 approval of Vobrig for central precocious puberty, and the HERO trial. DailyMed no longer serves the cited label version, so we checked it against the current rendering of the same label set.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products

    Profile summary

    Before
    A GnRH agonist. This profile cites a U.S. label record.
    After
    A GnRH agonist FDA-approved since 1985 under several names. The cited label covers palliative treatment of advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.

    Evidence note

    Before
    The cited DailyMed label identifies Leuprolide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    The label describes a controlled comparison with another hormone treatment in prostate cancer, and leuprolide served as the comparison treatment in a large randomized trial. Each leuprolide product has its own label and uses.

    Related names

    Before
    Leuprolide acetate
    After
    Leuprolide acetate, Lupron, Eligard, Vobrig

    Cited source records

    Before
    dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10
    After
    dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda020263-1993-04-16-d5ec3f5822e0, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-drugs-nda213150-2020-05-01-40513bba6c48, fda-vobrig-approval-2026, journal-pmid-32469183

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10]
    After
    U.S. National Library of Medicine [sources: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10]; U.S. Food and Drug Administration [sources: fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026]

    Claim citations

    Before
    name: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; aliases: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; category: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; status: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; summary: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; evidenceNote: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10
    After
    name: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; aliases: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; category: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; status: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; summary: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026; evidenceNote: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, journal-pmid-32469183
  56. Profile status changed

    Linaclotide profile

    We added a plain-language reader guide with cited answers, re-checked the Linzess label, and added Drugs@FDA approval records for Linzess and generic linaclotide.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Linzess

    Profile summary

    Before
    A guanylate cyclase-C agonist peptide. This profile cites a U.S. label record.
    After
    A guanylate cyclase-C agonist approved by FDA as Linzess for irritable bowel syndrome with constipation and chronic constipation in adults, and for certain uses in children.

    Evidence note

    Before
    The cited DailyMed label identifies Linaclotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    Large randomized, placebo-controlled trials described in the label support its adult uses. The label carries a boxed warning: it is contraindicated in children younger than 2 because of a risk of serious dehydration.

    Cited source records

    Before
    dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39
    After
    dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39, fda-drugs-nda202811-2012-08-30-4be8911e4fc0, fda-drugs-anda209564-2021-02-09-c16b14d7f4e0, fda-drugs-anda209611-2023-02-07-1f1bc2997a49

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39]
    After
    U.S. National Library of Medicine [sources: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39]; U.S. Food and Drug Administration [sources: fda-drugs-nda202811-2012-08-30-4be8911e4fc0]

    Claim citations

    Before
    name: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39; aliases: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39; category: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39; status: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39; summary: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39; evidenceNote: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39
    After
    name: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39; aliases: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39; category: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39; status: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39, fda-drugs-nda202811-2012-08-30-4be8911e4fc0; summary: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39, fda-drugs-nda202811-2012-08-30-4be8911e4fc0; evidenceNote: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39
  57. Profile status changed

    Liraglutide profile

    We added a plain-language reader guide with cited answers, re-checked the liraglutide label and the Drugs@FDA approval records, and added the LEADER trial report and FDA’s April 2026 503B proposal.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Victoza, Saxenda and generic versions

    Profile summary

    Before
    A GLP-1 receptor agonist. This profile cites a U.S. label record.
    After
    A GLP-1 receptor agonist approved by FDA as Victoza and Saxenda, with approved generic versions. Large randomized trials support its weight-management and cardiovascular evidence.

    Evidence note

    Before
    The cited DailyMed label identifies Liraglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    The cited generic weight-management label covers adults and children aged 12 and older with obesity, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA proposed in April 2026 to exclude liraglutide from the 503B bulks list.

    Related names

    Before
    Saxenda
    After
    Saxenda, Victoza

    Cited source records

    Before
    dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6, fda-glp1-label-warning-request-2026
    After
    dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6, fda-glp1-label-warning-request-2026, fda-drugs-nda022341-2010-01-25-97e5fbcce57e, fda-drugs-nda206321-2014-12-23-a195c56028d5, fda-drugs-anda215503-2024-12-23-56b69e4fa52c, fda-glp1-bulks-proposal-2026, journal-pmid-27295427

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6]
    After
    U.S. National Library of Medicine [sources: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6]; U.S. Food and Drug Administration [sources: fda-drugs-nda022341-2010-01-25-97e5fbcce57e, fda-glp1-bulks-proposal-2026]

    Claim citations

    Before
    name: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; aliases: fda-glp1-label-warning-request-2026; category: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; status: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; summary: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; evidenceNote: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6
    After
    name: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; aliases: fda-glp1-label-warning-request-2026, fda-drugs-nda022341-2010-01-25-97e5fbcce57e; category: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; status: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6, fda-drugs-nda022341-2010-01-25-97e5fbcce57e, fda-drugs-nda206321-2014-12-23-a195c56028d5, fda-drugs-anda215503-2024-12-23-56b69e4fa52c; summary: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6, fda-drugs-nda022341-2010-01-25-97e5fbcce57e, fda-drugs-nda206321-2014-12-23-a195c56028d5, fda-drugs-anda215503-2024-12-23-56b69e4fa52c, journal-pmid-27295427; evidenceNote: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6, fda-glp1-bulks-proposal-2026
  58. Profile status changed

    Lixisenatide profile

    We added a plain-language reader guide with cited answers drawn from the Adlyxin and Soliqua 100/33 labels, and added the Drugs@FDA approval record for Adlyxin.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Adlyxin and in Soliqua 100/33

    Profile summary

    Before
    A GLP-1 receptor agonist component. This profile cites a U.S. combination-product label.
    After
    A GLP-1 receptor agonist approved by FDA as Adlyxin, and in combination with insulin glargine as Soliqua 100/33, to improve blood-sugar control in adults with type 2 diabetes.

    Evidence note

    Before
    The cited DailyMed label identifies Lixisenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    Large randomized trials described in the labels support these uses. In the ELIXA trial of 6,068 adults after a recent acute coronary syndrome, the results ruled out a prespecified increase in major cardiovascular risk compared with placebo.

    Related names

    Before
    Soliqua 100/33
    After
    Soliqua 100/33, Adlyxin

    Cited source records

    Before
    dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25, fda-adlyxin-label-2024
    After
    dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25, fda-adlyxin-label-2024, fda-drugs-bla208471-2016-07-27-6e0355642026

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25]
    After
    U.S. National Library of Medicine [sources: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25]; U.S. Food and Drug Administration [sources: fda-drugs-bla208471-2016-07-27-6e0355642026, fda-adlyxin-label-2024]

    Claim citations

    Before
    name: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; aliases: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; category: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; status: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; summary: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; evidenceNote: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25
    After
    name: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; aliases: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25, fda-adlyxin-label-2024, fda-drugs-bla208471-2016-07-27-6e0355642026; category: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; status: fda-drugs-bla208471-2016-07-27-6e0355642026, fda-adlyxin-label-2024, dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25; summary: fda-adlyxin-label-2024, dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25, fda-drugs-bla208471-2016-07-27-6e0355642026; evidenceNote: fda-adlyxin-label-2024, dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25
  59. Profile status changed

    Maridebart cafraglutide profile

    We added a plain-language reader guide with cited answers, Phase 2 results from our human evidence review, and retained ClinicalTrials.gov records for Phase 3 trials.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    Investigational
    After
    In clinical trials; not FDA-approved

    Profile summary

    Before
    An antibody-peptide conjugate candidate. This profile cites a completed ClinicalTrials.gov study record.
    After
    An experimental Amgen antibody-peptide conjugate, also called MariTide, that blocks the GIP receptor and activates the GLP-1 receptor. It is in Phase 3 trials and not FDA-approved.

    Evidence note

    Before
    ClinicalTrials.gov lists an Amgen bioavailability study as completed, updated July 21, 2026.
    After
    A large 52-week randomized Phase 2 trial reported weight loss compared with placebo in people with obesity, with common gastrointestinal side effects. Phase 3 trials, including a cardiovascular outcomes trial, are registered.

    Cited source records

    Before
    ctg-nct07717814-v1
    After
    ctg-nct07717814-v1, journal-pmid-40549887, ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3, ctg-observation-nct07037433-2026-07-24-ae9704758762, ctg-observation-nct07037459-2026-07-02-199638062a19, ctg-observation-nct06660173-2026-09-11-dfcf2dd8720e

    Claim citations

    Before
    name: ctg-nct07717814-v1; aliases: ctg-nct07717814-v1; category: ctg-nct07717814-v1; status: ctg-nct07717814-v1; summary: ctg-nct07717814-v1; evidenceNote: ctg-nct07717814-v1
    After
    name: ctg-nct07717814-v1; aliases: ctg-nct07717814-v1; category: ctg-nct07717814-v1; status: ctg-nct07717814-v1, ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3, ctg-observation-nct07037433-2026-07-24-ae9704758762; summary: ctg-nct07717814-v1, journal-pmid-40549887, ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3; evidenceNote: journal-pmid-40549887, ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3, ctg-observation-nct07037433-2026-07-24-ae9704758762
  60. Profile status changed

    MOTS-c profile

    We added a plain-language reader guide with cited answers, re-checked FDA’s MOTS-c briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists MOTS-c acetate. FDA has not issued a final 503A rule.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    FDA compounding assessment in the cited records
    After
    Not an FDA-approved drug

    Profile summary

    Before
    A mitochondrial-derived peptide represented in FDA compounding-risk and advisory-committee records.
    After
    A 16-amino-acid mitochondrial peptide that is not FDA-approved. FDA’s 2026 review found no studies of MOTS-c in people.

    Evidence note

    Before
    FDA's July 2026 briefing evaluates MOTS-c-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
    After
    FDA staff recommended in May 2026 against adding MOTS-c to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists MOTS-c acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make MOTS-c an FDA-approved drug.

    Related names

    Before
    MOTS-C
    After
    MOTS-C, Mitochondrial open reading frame of the 12S rRNA-c

    Cited source records

    Before
    fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026
    After
    fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026, federal-register-2026-07361-0aed508462b2, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026

    Named organizations

    Before
    U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026]
    After
    U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]

    Claim citations

    Before
    name: fda-mots-c-briefing; aliases: fda-mots-c-briefing; category: fda-bulk-peptide-risks, fda-mots-c-briefing; status: fda-mots-c-briefing; summary: fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-mots-c-briefing
    After
    name: fda-mots-c-briefing; aliases: fda-mots-c-briefing; category: fda-bulk-peptide-risks, fda-mots-c-briefing; status: fda-mots-c-briefing; summary: fda-mots-c-briefing; evidenceNote: fda-mots-c-briefing, fda-pcac-peptide-meeting-2026, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
  61. Profile status changed

    Octreotide profile

    We added a plain-language reader guide with cited answers, re-checked the generic octreotide label, and added Drugs@FDA approval records and two randomized acromegaly trials from our human evidence review.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Sandostatin and other octreotide products

    Profile summary

    Before
    A somatostatin analogue. This profile cites a U.S. label record.
    After
    A somatostatin analogue first approved by FDA as Sandostatin in 1988, used for acromegaly and for diarrhea and flushing caused by certain hormone-secreting tumors.

    Evidence note

    Before
    The cited DailyMed label identifies Octreotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    The cited label states that its trials did not show improvement in symptoms or tumor size. Smaller randomized trials in acromegaly report lower growth hormone and IGF-1 levels.

    Related names

    Before
    Octreotide acetate
    After
    Octreotide acetate, Sandostatin

    Cited source records

    Before
    dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2
    After
    dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098, journal-pmid-2229278, journal-pmid-34953531

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2]
    After
    U.S. National Library of Medicine [sources: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2]; U.S. Food and Drug Administration [sources: fda-drugs-nda019667-1988-10-21-b49b130f234b]

    Claim citations

    Before
    name: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; aliases: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; category: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; status: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; summary: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; evidenceNote: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2
    After
    name: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; aliases: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; category: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; status: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098; summary: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; evidenceNote: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, journal-pmid-2229278, journal-pmid-34953531
  62. Profile status changed

    Pemvidutide profile

    We added a plain-language reader guide with cited answers, IMPACT trial results from our human evidence review, and retained ClinicalTrials.gov records for later trials, including a Phase 3 trial in MASH.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    Investigational
    After
    In clinical trials; not FDA-approved

    Profile summary

    Before
    A glucagon/GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.
    After
    An experimental Altimmune glucagon and GLP-1 receptor agonist studied in the liver disease MASH. It is not FDA-approved.

    Evidence note

    Before
    ClinicalTrials.gov lists Altimmune's IMPACT study as completed, last updated May 18, 2026.
    After
    A 24-week randomized Phase 2 trial met its MASH-resolution goal but not its fibrosis goal. A Phase 3 trial in MASH was recruiting in August 2026.

    Cited source records

    Before
    ctg-nct05989711-v10
    After
    ctg-nct05989711-v10, journal-pmid-41237796, ctg-observation-nct07795164-2026-08-31-445923515599, ctg-observation-nct06987513-2026-07-31-1e0339600b69, ctg-observation-nct07009860-2026-03-20-c02a1977625c

    Claim citations

    Before
    name: ctg-nct05989711-v10; aliases: ctg-nct05989711-v10; category: ctg-nct05989711-v10; status: ctg-nct05989711-v10; summary: ctg-nct05989711-v10; evidenceNote: ctg-nct05989711-v10
    After
    name: ctg-nct05989711-v10; aliases: ctg-nct05989711-v10; category: ctg-nct05989711-v10; status: ctg-nct05989711-v10, ctg-observation-nct07795164-2026-08-31-445923515599; summary: ctg-nct05989711-v10, journal-pmid-41237796; evidenceNote: journal-pmid-41237796, ctg-observation-nct07795164-2026-08-31-445923515599
  63. Profile status changed

    Petrelintide profile

    We added a plain-language reader guide with cited answers, Phase 1 results from our human evidence review, and retained ClinicalTrials.gov records for Phase 2 and Phase 3 trials.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    Investigational
    After
    In clinical trials; not FDA-approved

    Profile summary

    Before
    An amylin analogue candidate. This profile cites a ClinicalTrials.gov study record that was not yet recruiting.
    After
    An experimental amylin analogue from Zealand Pharma and Roche, in Phase 3 trials. It is not FDA-approved.

    Evidence note

    Before
    ClinicalTrials.gov lists a Roche-sponsored combination study as not yet recruiting, updated July 7, 2026.
    After
    The only published human results reviewed here are from two small randomized Phase 1 trials, which reported weight reductions. Phase 2 trials are listed as completed without results in the sources cited, and Phase 3 trials were recruiting in late 2026.

    Cited source records

    Before
    ctg-nct07589686-v3
    After
    ctg-nct07589686-v3, journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct06926842-2026-09-09-66566db76c0b, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d

    Named organizations

    Before
    Hoffmann-La Roche [sources: ctg-nct07589686-v3]
    After
    Hoffmann-La Roche [sources: ctg-nct07589686-v3]; Zealand Pharma [sources: ctg-observation-nct06662539-2026-03-23-25a9d8533efb]

    Claim citations

    Before
    name: ctg-nct07589686-v3; aliases: ctg-nct07589686-v3; category: ctg-nct07589686-v3; status: ctg-nct07589686-v3; summary: ctg-nct07589686-v3; evidenceNote: ctg-nct07589686-v3
    After
    name: ctg-nct07589686-v3; aliases: ctg-nct07589686-v3; category: ctg-nct07589686-v3; status: ctg-nct07589686-v3, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d; summary: ctg-nct07589686-v3, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b; evidenceNote: journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
  64. Profile status changed

    Plecanatide profile

    We added a plain-language reader guide with cited answers, re-checked the Trulance label, and added the Drugs@FDA approval record.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Trulance

    Profile summary

    Before
    A guanylate cyclase-C agonist peptide. This profile cites a U.S. label record.
    After
    A guanylate cyclase-C agonist approved by FDA as Trulance for chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.

    Evidence note

    Before
    The cited DailyMed label identifies Plecanatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    Four large 12-week randomized, placebo-controlled trials described in the label support its uses. The label carries a boxed warning about serious dehydration in children.

    Cited source records

    Before
    dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15
    After
    dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15, fda-drugs-nda208745-2017-01-19-830a6b2585ac

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15]
    After
    U.S. National Library of Medicine [sources: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15]; U.S. Food and Drug Administration [sources: fda-drugs-nda208745-2017-01-19-830a6b2585ac]

    Claim citations

    Before
    name: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15; aliases: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15; category: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15; status: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15; summary: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15; evidenceNote: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15
    After
    name: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15; aliases: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15; category: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15; status: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15, fda-drugs-nda208745-2017-01-19-830a6b2585ac; summary: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15, fda-drugs-nda208745-2017-01-19-830a6b2585ac; evidenceNote: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15
  65. Profile status changed

    Pramlintide profile

    We added a plain-language reader guide with cited answers, re-checked the Symlin label, and added the Drugs@FDA approval record.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Symlin

    Profile summary

    Before
    An amylin analogue. This profile cites a U.S. label record.
    After
    An amylin analogue approved by FDA as Symlin, an add-on for people with type 1 or type 2 diabetes who use mealtime insulin.

    Evidence note

    Before
    The cited DailyMed label identifies Pramlintide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    Large randomized, placebo-controlled trials described in the label found modest additional HbA1c reductions. The label carries a boxed warning about severe low blood sugar when used with insulin.

    Related names

    Before
    SymlinPen
    After
    SymlinPen, Symlin

    Cited source records

    Before
    dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18
    After
    dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18, fda-drugs-nda021332-2005-03-16-bb1cb7c1a09e

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18]
    After
    U.S. National Library of Medicine [sources: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18]; U.S. Food and Drug Administration [sources: fda-drugs-nda021332-2005-03-16-bb1cb7c1a09e]

    Claim citations

    Before
    name: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18; aliases: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18; category: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18; status: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18; summary: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18; evidenceNote: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18
    After
    name: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18; aliases: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18, fda-drugs-nda021332-2005-03-16-bb1cb7c1a09e; category: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18; status: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18, fda-drugs-nda021332-2005-03-16-bb1cb7c1a09e; summary: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18, fda-drugs-nda021332-2005-03-16-bb1cb7c1a09e; evidenceNote: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18
  66. Profile status changed

    Retatrutide profile

    We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which states that retatrutide cannot be used in compounding.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    Investigational
    After
    In clinical trials; not FDA-approved

    Profile summary

    Before
    A multi-receptor metabolic candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.
    After
    An experimental GIP, GLP-1 and glucagon receptor agonist from Eli Lilly. FDA says it is not an approved drug and cannot be used in compounding.

    Evidence note

    Before
    ClinicalTrials.gov lists an Eli Lilly study as active, not recruiting, with a registry update posted July 20, 2026.
    After
    Published randomized trials, including a Phase 3 diabetes trial, report weight and blood-sugar changes over up to 48 weeks. FDA states that retatrutide has not been found safe and effective for any condition and has warned companies marketing it to consumers.

    Cited source records

    Before
    ctg-nct06297603-v25
    After
    ctg-nct06297603-v25, fda-unapproved-glp1-concerns-2026-r2, journal-pmid-37366315, journal-pmid-37385280, journal-pmid-42250575, ctg-observation-nct05882045-2026-07-30-d21e38ddcccc, ctg-observation-nct05929079-2026-07-30-d0cad2c0ebfa, ctg-observation-nct05929066-2026-08-21-fa2b7b67fa10, ctg-observation-nct06383390-2026-08-24-4bb37a90f79a, ctg-observation-nct06297603-2026-11-13-c86dcf0120ca

    Named organizations

    Before
    Eli Lilly and Company [sources: ctg-nct06297603-v25]
    After
    Eli Lilly and Company [sources: ctg-nct06297603-v25]; U.S. Food and Drug Administration [sources: fda-unapproved-glp1-concerns-2026-r2]

    Claim citations

    Before
    name: ctg-nct06297603-v25; aliases: ctg-nct06297603-v25; category: ctg-nct06297603-v25; status: ctg-nct06297603-v25; summary: ctg-nct06297603-v25; evidenceNote: ctg-nct06297603-v25
    After
    name: ctg-nct06297603-v25; aliases: ctg-nct06297603-v25; category: ctg-nct06297603-v25; status: ctg-nct06297603-v25, ctg-observation-nct06297603-2026-11-13-c86dcf0120ca, fda-unapproved-glp1-concerns-2026-r2; summary: ctg-nct06297603-v25, journal-pmid-42250575, fda-unapproved-glp1-concerns-2026-r2; evidenceNote: journal-pmid-37366315, journal-pmid-42250575, fda-unapproved-glp1-concerns-2026-r2
  67. Profile status changed

    Semaglutide profile

    We added a plain-language reader guide with cited answers, re-checked the Wegovy label and the Drugs@FDA approval records, and added FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026) and its April 2026 503B proposal. An August 2026 Ozempic supplement changed carton labeling only and is not reflected.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Ozempic, Rybelsus and Wegovy

    Profile summary

    Before
    A GLP-1 receptor agonist. This profile cites a Wegovy label and an FDA notice.
    After
    A GLP-1 receptor agonist approved by FDA as Ozempic, Rybelsus and Wegovy. Its approved uses rest on large randomized trials described in the label.

    Evidence note

    Before
    The cited DailyMed label identifies Semaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    The Wegovy label covers weight reduction, cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and MASH under accelerated approval, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA says compounded and other unapproved semaglutide products are not FDA-approved.

    Cited source records

    Before
    dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026, fda-semaglutide-identity
    After
    dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026, fda-semaglutide-identity, fda-drugs-nda209637-2017-12-05-0b9e82eeabee, fda-drugs-nda213051-2019-09-20-2bce5be175e9, fda-drugs-nda215256-2021-06-04-bead2c63a813, fda-drugs-nda218316-2025-12-22-e39b0518156a, fda-glp1-label-warning-request-2026, fda-glp1-bulks-proposal-2026, fda-unapproved-glp1-concerns-2026-r2

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19]
    After
    U.S. National Library of Medicine [sources: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19]; U.S. Food and Drug Administration [sources: fda-drugs-nda209637-2017-12-05-0b9e82eeabee, fda-unapproved-glp1-concerns-2026-r2]

    Claim citations

    Before
    name: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; aliases: fda-semaglutide-identity; category: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; status: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; summary: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026; evidenceNote: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19
    After
    name: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; aliases: fda-semaglutide-identity; category: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; status: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-drugs-nda209637-2017-12-05-0b9e82eeabee, fda-drugs-nda213051-2019-09-20-2bce5be175e9, fda-drugs-nda215256-2021-06-04-bead2c63a813; summary: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-drugs-nda209637-2017-12-05-0b9e82eeabee, fda-drugs-nda213051-2019-09-20-2bce5be175e9, fda-drugs-nda215256-2021-06-04-bead2c63a813; evidenceNote: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-unapproved-glp1-concerns-2026-r2
  68. Profile status changed

    Semax profile

    We added a plain-language reader guide with cited answers, re-checked FDA’s Semax briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists Semax free base. FDA has not issued a final 503A rule.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    FDA compounding assessment in the cited records
    After
    Not an FDA-approved drug

    Profile summary

    Before
    A synthetic peptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.
    After
    A synthetic seven-amino-acid peptide that is not FDA-approved in the United States. FDA’s 2026 review found only small, incompletely reported human studies.

    Evidence note

    Before
    FDA's July 2026 briefing evaluates Semax-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
    After
    FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists Semax free base among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make Semax an FDA-approved drug.

    Cited source records

    Before
    fda-semax-briefing, fda-pcac-peptide-meeting-2026
    After
    fda-semax-briefing, fda-pcac-peptide-meeting-2026, fda-bulk-peptide-risks, federal-register-2026-07361-0aed508462b2, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026

    Named organizations

    Before
    U.S. Food and Drug Administration [sources: fda-semax-briefing, fda-pcac-peptide-meeting-2026]
    After
    U.S. Food and Drug Administration [sources: fda-semax-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]

    Claim citations

    Before
    name: fda-semax-briefing; aliases: fda-semax-briefing; category: fda-semax-briefing, fda-pcac-peptide-meeting-2026; status: fda-semax-briefing; summary: fda-semax-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-semax-briefing
    After
    name: fda-semax-briefing; aliases: fda-semax-briefing; category: fda-semax-briefing, fda-pcac-peptide-meeting-2026; status: fda-semax-briefing; summary: fda-semax-briefing; evidenceNote: fda-semax-briefing, fda-pcac-peptide-meeting-2026, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
  69. Profile status changed

    Setmelanotide profile

    We added a plain-language reader guide with cited answers, re-checked the Imcivree label, and added the Drugs@FDA approval record.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Imcivree for specific rare causes of obesity

    Profile summary

    Before
    A melanocortin-4 receptor agonist. This profile cites a U.S. label record.
    After
    An MC4 receptor agonist approved by FDA as Imcivree for acquired hypothalamic obesity, Bardet-Biedl syndrome and certain genetic deficiencies, not for general obesity.

    Evidence note

    Before
    The cited DailyMed label identifies Setmelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    A randomized, placebo-controlled trial in 142 people with acquired hypothalamic obesity and smaller open-label trials in genetic forms of obesity are described in the label. The label states that it is not indicated for general obesity.

    Cited source records

    Before
    dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14
    After
    dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14, fda-drugs-nda213793-2020-11-25-5c2792fff70d

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14]
    After
    U.S. National Library of Medicine [sources: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14]; U.S. Food and Drug Administration [sources: fda-drugs-nda213793-2020-11-25-5c2792fff70d]

    Claim citations

    Before
    name: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14; aliases: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14; category: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14; status: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14; summary: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14; evidenceNote: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14
    After
    name: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14; aliases: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14; category: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14; status: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14, fda-drugs-nda213793-2020-11-25-5c2792fff70d; summary: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14, fda-drugs-nda213793-2020-11-25-5c2792fff70d; evidenceNote: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14
  70. Profile status changed

    Survodutide profile

    We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which names survodutide among unapproved drugs sold with false research-use labels.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    Investigational
    After
    In clinical trials; not FDA-approved

    Profile summary

    Before
    A glucagon/GLP-1 receptor agonist candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.
    After
    An experimental glucagon and GLP-1 receptor dual agonist from Boehringer Ingelheim, studied in obesity and fatty liver disease. It is not FDA-approved.

    Evidence note

    Before
    ClinicalTrials.gov lists a Boehringer Ingelheim study as active, not recruiting, updated July 22, 2026.
    After
    Published randomized trials, including the Phase 3 SYNCHRONIZE-1 trial, report weight loss and liver-fat reductions. A completed cardiovascular safety trial has no results in the cited sources. FDA has warned companies selling unapproved survodutide with false research-use labels.

    Cited source records

    Before
    ctg-nct05202353-v50
    After
    ctg-nct05202353-v50, fda-unapproved-glp1-concerns-2026-r2, journal-pmid-38330987, journal-pmid-38847460, journal-pmid-42253238, journal-pmid-42252333, ctg-observation-nct06077864-2026-08-11-60e24ca2b385, ctg-observation-nct06632444-2026-08-10-1ea3a43e551b, ctg-observation-nct07754461-2026-08-10-d71d6065261a

    Named organizations

    Before
    Boehringer Ingelheim [sources: ctg-nct05202353-v50]
    After
    Boehringer Ingelheim [sources: ctg-nct05202353-v50]; U.S. Food and Drug Administration [sources: fda-unapproved-glp1-concerns-2026-r2]

    Claim citations

    Before
    name: ctg-nct05202353-v50; aliases: ctg-nct05202353-v50; category: ctg-nct05202353-v50; status: ctg-nct05202353-v50; summary: ctg-nct05202353-v50; evidenceNote: ctg-nct05202353-v50
    After
    name: ctg-nct05202353-v50; aliases: ctg-nct05202353-v50; category: ctg-nct05202353-v50; status: ctg-nct05202353-v50, ctg-observation-nct07754461-2026-08-10-d71d6065261a, fda-unapproved-glp1-concerns-2026-r2; summary: ctg-nct05202353-v50, journal-pmid-38330987, journal-pmid-42253238, fda-unapproved-glp1-concerns-2026-r2; evidenceNote: journal-pmid-42253238, journal-pmid-42252333, ctg-observation-nct06077864-2026-08-11-60e24ca2b385, fda-unapproved-glp1-concerns-2026-r2
  71. Profile status changed

    TB-500 profile

    We added a plain-language reader guide with cited answers, re-checked FDA’s TB-500 briefing, added a registered trial, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists TB-500 acetate. FDA has not issued a final 503A rule.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    FDA compounding assessment in the cited records
    After
    Not an FDA-approved drug

    Profile summary

    Before
    A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.
    After
    A synthetic seven-amino-acid fragment of thymosin beta-4 that is not FDA-approved. FDA’s 2026 review found no studies of TB-500 in people.

    Evidence note

    Before
    FDA's July 2026 briefing evaluates TB-500-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
    After
    FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists TB-500 acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make TB-500 an FDA-approved drug.

    Cited source records

    Before
    fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026
    After
    fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026, fda-bulk-peptide-risks, ctg-observation-nct07487363-2026-03-23-eb4b60623fcf, federal-register-2026-07361-0aed508462b2, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026

    Named organizations

    Before
    U.S. Food and Drug Administration [sources: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026]
    After
    U.S. Food and Drug Administration [sources: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]

    Claim citations

    Before
    name: fda-tb-500-identity, fda-tb-500-briefing; aliases: fda-tb-500-identity, fda-tb-500-briefing; category: fda-tb-500-briefing; status: fda-tb-500-briefing; summary: fda-tb-500-identity, fda-tb-500-briefing; evidenceNote: fda-tb-500-briefing
    After
    name: fda-tb-500-identity, fda-tb-500-briefing; aliases: fda-tb-500-identity, fda-tb-500-briefing; category: fda-tb-500-briefing; status: fda-tb-500-briefing; summary: fda-tb-500-briefing; evidenceNote: fda-tb-500-briefing, fda-pcac-peptide-meeting-2026, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
  72. Profile status changed

    Teriparatide profile

    We added a plain-language reader guide with cited answers, re-checked the generic teriparatide label, and added Drugs@FDA approval records for teriparatide products.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Forteo and other teriparatide products

    Profile summary

    Before
    A parathyroid hormone analogue. This profile cites a U.S. label record.
    After
    A parathyroid hormone analogue first approved by FDA as Forteo in 2002 for osteoporosis at high risk of fracture.

    Evidence note

    Before
    The cited DailyMed label identifies Teriparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    A large randomized, placebo-controlled trial described in the label found fewer new spine fractures than placebo. The label states that teriparatide caused osteosarcoma in rats; an increased risk has not been observed in human observational studies.

    Related names

    Before
    None recorded
    After
    Forteo

    Cited source records

    Before
    dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9
    After
    dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9, fda-drugs-nda021318-2002-11-26-2f4c2df07e0a, fda-drugs-nda211939-2019-10-04-4790820cc8d4, fda-drugs-anda211097-2023-11-16-2855aa79a2e2, fda-drugs-nda218771-2024-06-04-4293d16697eb

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9]
    After
    U.S. National Library of Medicine [sources: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9]; U.S. Food and Drug Administration [sources: fda-drugs-nda021318-2002-11-26-2f4c2df07e0a]

    Claim citations

    Before
    name: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9; aliases: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9; category: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9; status: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9; summary: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9; evidenceNote: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9
    After
    name: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9; aliases: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9, fda-drugs-nda021318-2002-11-26-2f4c2df07e0a; category: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9; status: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9, fda-drugs-nda021318-2002-11-26-2f4c2df07e0a, fda-drugs-nda211939-2019-10-04-4790820cc8d4, fda-drugs-anda211097-2023-11-16-2855aa79a2e2, fda-drugs-nda218771-2024-06-04-4293d16697eb; summary: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9, fda-drugs-nda021318-2002-11-26-2f4c2df07e0a; evidenceNote: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9
  73. Profile status changed

    Tesamorelin profile

    We added a plain-language reader guide with cited answers, re-checked the Egrifta SV label, and added the Drugs@FDA approval record.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Egrifta for HIV-associated abdominal fat

    Profile summary

    Before
    A growth-hormone-releasing factor analogue. This profile cites a U.S. label record.
    After
    A growth hormone-releasing factor analogue approved by FDA as Egrifta to reduce excess abdominal fat in adults with HIV and lipodystrophy.

    Evidence note

    Before
    The cited DailyMed label identifies Tesamorelin and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    Two randomized, placebo-controlled trials described in the label found larger reductions in visceral abdominal fat than placebo. The label states that it is not indicated for weight loss and that long-term cardiovascular safety has not been established.

    Cited source records

    Before
    dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9
    After
    dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9, fda-drugs-bla022505-2010-11-10-9cc235ae6ce0

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9]
    After
    U.S. National Library of Medicine [sources: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9]; U.S. Food and Drug Administration [sources: fda-drugs-bla022505-2010-11-10-9cc235ae6ce0]

    Claim citations

    Before
    name: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; aliases: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; category: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; status: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; summary: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; evidenceNote: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9
    After
    name: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; aliases: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; category: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9; status: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9, fda-drugs-bla022505-2010-11-10-9cc235ae6ce0; summary: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9, fda-drugs-bla022505-2010-11-10-9cc235ae6ce0; evidenceNote: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9
  74. Profile status changed

    Tirzepatide profile

    We added a plain-language reader guide with cited answers, re-checked the Zepbound label and Drugs@FDA records, and added FDA’s August 2026 approval of a cardiovascular indication for Mounjaro, the SURPASS-CVOT label updates for Mounjaro and Zepbound, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026).

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Mounjaro and Zepbound

    Profile summary

    Before
    A GIP and GLP-1 receptor agonist. This profile cites a Zepbound label and an FDA notice.
    After
    A GIP and GLP-1 receptor agonist approved by FDA as Mounjaro and Zepbound. In August 2026 FDA added a cardiovascular risk-reduction indication for Mounjaro.

    Evidence note

    Before
    The cited DailyMed label identifies Tirzepatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    The Zepbound label covers weight reduction and obstructive sleep apnea in adults with obesity and carries a boxed warning about thyroid C-cell tumors in rats. FDA’s August 2026 letters add a cardiovascular indication for Mounjaro and SURPASS-CVOT results to both labels. FDA says compounded and other unapproved tirzepatide products are not FDA-approved.

    Cited source records

    Before
    dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-tirzepatide-2023, fda-tirzepatide-identity
    After
    dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-tirzepatide-2023, fda-tirzepatide-identity, fda-drugs-nda215866-2022-05-13-20c7192d69ff, fda-drugs-nda217806-2023-11-08-1fa405392d95, fda-mounjaro-s044-s045-approval-2026, fda-zepbound-s041-approval-2026, fda-glp1-label-warning-request-2026, fda-glp1-bulks-proposal-2026, fda-unapproved-glp1-concerns-2026-r2

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40]
    After
    U.S. National Library of Medicine [sources: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40]; U.S. Food and Drug Administration [sources: fda-mounjaro-s044-s045-approval-2026, fda-unapproved-glp1-concerns-2026-r2]

    Claim citations

    Before
    name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; aliases: fda-tirzepatide-identity; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-tirzepatide-2023; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40
    After
    name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; aliases: fda-tirzepatide-identity; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-drugs-nda215866-2022-05-13-20c7192d69ff, fda-drugs-nda217806-2023-11-08-1fa405392d95; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-drugs-nda215866-2022-05-13-20c7192d69ff, fda-drugs-nda217806-2023-11-08-1fa405392d95, fda-mounjaro-s044-s045-approval-2026; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-mounjaro-s044-s045-approval-2026, fda-zepbound-s041-approval-2026, fda-unapproved-glp1-concerns-2026-r2
  75. Profile status changed

    Vosoritide profile

    We added a plain-language reader guide with cited answers, re-checked the Voxzogo label, and added the Drugs@FDA approval record.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Voxzogo under accelerated approval for achondroplasia

    Profile summary

    Before
    A C-type natriuretic peptide analogue. This profile cites a U.S. label record.
    After
    A C-type natriuretic peptide analogue approved by FDA as Voxzogo, under accelerated approval, to increase linear growth in children with achondroplasia whose growth plates are open.

    Evidence note

    Before
    The cited DailyMed label identifies Vosoritide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    A 52-week randomized, placebo-controlled trial in 121 children described in the label found faster annual growth than with placebo. Continued approval may depend on confirmatory trials of clinical benefit.

    Cited source records

    Before
    dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16
    After
    dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16, fda-drugs-nda214938-2021-11-19-6bf5863742a4

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16]
    After
    U.S. National Library of Medicine [sources: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16]; U.S. Food and Drug Administration [sources: fda-drugs-nda214938-2021-11-19-6bf5863742a4]

    Claim citations

    Before
    name: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16; aliases: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16; category: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16; status: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16; summary: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16; evidenceNote: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16
    After
    name: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16; aliases: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16; category: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16; status: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16, fda-drugs-nda214938-2021-11-19-6bf5863742a4; summary: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16, fda-drugs-nda214938-2021-11-19-6bf5863742a4; evidenceNote: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16
  76. Profile status changed

    Ziconotide profile

    We added a plain-language reader guide with cited answers, re-checked the Prialt label, and added the Drugs@FDA approval record.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Status

    Before
    U.S. label record
    After
    FDA-approved as Prialt for severe chronic pain

    Profile summary

    Before
    A synthetic peptide. This profile cites a U.S. intrathecal-drug label.
    After
    An N-type calcium channel blocker approved by FDA as Prialt for severe chronic pain in certain adults who cannot tolerate or did not respond to other treatments.

    Evidence note

    Before
    The cited DailyMed label identifies Ziconotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
    After
    Smaller placebo-controlled trials described in the label found greater short-term pain relief than placebo. The label carries a boxed warning about severe psychiatric symptoms and neurological impairment.

    Cited source records

    Before
    dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6
    After
    dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6, fda-drugs-nda021060-2004-12-28-20b261a9bf76

    Named organizations

    Before
    U.S. National Library of Medicine [sources: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6]
    After
    U.S. National Library of Medicine [sources: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6]; U.S. Food and Drug Administration [sources: fda-drugs-nda021060-2004-12-28-20b261a9bf76]

    Claim citations

    Before
    name: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6; aliases: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6; category: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6; status: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6; summary: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6; evidenceNote: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6
    After
    name: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6; aliases: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6; category: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6; status: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6, fda-drugs-nda021060-2004-12-28-20b261a9bf76; summary: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6, fda-drugs-nda021060-2004-12-28-20b261a9bf76; evidenceNote: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6
  77. Profile updated

    BPC-157 profile

    We added a plain-language reader guide with cited answers, re-checked FDA’s BPC-157 records, added a second registered trial, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists BPC-157. FDA has not issued a final 503A rule.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A research peptide represented by FDA compounding-review material and one selected trial-registry record.
    After
    A 15-amino-acid research peptide that is not FDA-approved. FDA’s 2026 review found only a few small, short human studies.

    Evidence note

    Before
    FDA presented BPC-157 briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding and FDA's final determination remains pending; the cited trial registration also does not establish safety or effectiveness.
    After
    FDA staff recommended in May 2026 against adding BPC-157 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists BPC-157 among six peptides that may be compounded under set conditions without federal enforcement action; it does not make BPC-157 an FDA-approved drug.

    Related names

    Before
    Body protection compound 157
    After
    Body protection compound 157, Bepecin, PL 14736

    Cited source records

    Before
    fda-bpc-157-briefing, fda-bulk-peptide-risks, ctg-nct07437547-v1, fda-pcac-peptide-meeting-2026
    After
    fda-bpc-157-briefing, fda-bulk-peptide-risks, ctg-nct07437547-v1, fda-pcac-peptide-meeting-2026, ctg-observation-nct07803250-2026-09-03-67a2d48128fc, federal-register-2026-07361-0aed508462b2, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026

    Named organizations

    Before
    U.S. Food and Drug Administration [sources: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026]; Hudson Biotech [sources: ctg-nct07437547-v1]
    After
    U.S. Food and Drug Administration [sources: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026]; Hudson Biotech [sources: ctg-nct07437547-v1]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]

    Claim citations

    Before
    name: fda-bpc-157-briefing; aliases: fda-bpc-157-briefing; category: fda-bpc-157-briefing, fda-bulk-peptide-risks, fda-pcac-peptide-meeting-2026; status: fda-bpc-157-briefing; summary: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026, ctg-nct07437547-v1; evidenceNote: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026, ctg-nct07437547-v1
    After
    name: fda-bpc-157-briefing; aliases: fda-bpc-157-briefing; category: fda-bpc-157-briefing, fda-bulk-peptide-risks, fda-pcac-peptide-meeting-2026; status: fda-bpc-157-briefing; summary: fda-bpc-157-briefing; evidenceNote: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
  78. Profile updated

    CJC-1295 profile

    We added a plain-language reader guide with cited answers, re-checked FDA’s CJC-1295 evaluation and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include CJC-1295.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    FDA evaluates CJC-1295 and CJC-1295 with drug affinity complex (DAC) as distinct active moieties, with several salt forms.
    After
    A synthetic GHRH analogue that is not FDA-approved. FDA treats CJC-1295 and CJC-1295 with DAC as distinct substances and found only small, short studies in healthy adults.

    Evidence note

    Before
    FDA's 2024 briefing distinguishes five bulk substances and reports that none is a component of an FDA-approved drug. Evidence for a DAC-modified substance cannot automatically establish effects for a non-DAC form.
    After
    FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among substances that may present significant safety risks. CJC-1295 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.

    Cited source records

    Before
    fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-cjc-1295-briefing-2024
    After
    fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-cjc-1295-briefing-2024, federal-register-2024-24828-d546fa8a5f55, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026

    Named organizations

    Before
    U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]
    After
    U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]

    Claim citations

    Before
    name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-cjc-1295-briefing-2024; evidenceNote: fda-cjc-1295-briefing-2024
    After
    name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-cjc-1295-briefing-2024; evidenceNote: fda-cjc-1295-briefing-2024, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
  79. Profile updated

    Emideltide profile

    We added a plain-language reader guide with cited answers, re-checked FDA’s emideltide briefing and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include emideltide.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A peptide also called DSIP in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.
    After
    A nine-amino-acid peptide, also called DSIP, that is not FDA-approved. FDA’s 2026 review found its human studies small and inconclusive.

    Evidence note

    Before
    FDA's July 2026 briefing evaluates Emideltide-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
    After
    FDA staff recommended in 2026 against adding emideltide or emideltide acetate to the 503A compounding list. Emideltide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.

    Related names

    Before
    DSIP
    After
    DSIP, Delta sleep-inducing peptide

    Cited source records

    Before
    fda-emideltide-briefing, fda-pcac-peptide-meeting-2026
    After
    fda-emideltide-briefing, fda-pcac-peptide-meeting-2026, federal-register-2026-07361-0aed508462b2, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026

    Named organizations

    Before
    U.S. Food and Drug Administration [sources: fda-emideltide-briefing, fda-pcac-peptide-meeting-2026]
    After
    U.S. Food and Drug Administration [sources: fda-emideltide-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]

    Claim citations

    Before
    name: fda-emideltide-briefing; aliases: fda-emideltide-briefing; category: fda-emideltide-briefing, fda-pcac-peptide-meeting-2026; status: fda-emideltide-briefing; summary: fda-emideltide-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-emideltide-briefing
    After
    name: fda-emideltide-briefing; aliases: fda-emideltide-briefing; category: fda-emideltide-briefing, fda-pcac-peptide-meeting-2026; status: fda-emideltide-briefing; summary: fda-emideltide-briefing; evidenceNote: fda-emideltide-briefing, hhs-503a-peptide-enforcement-discretion-policy-2026
  80. Profile updated

    GHK-Cu profile

    We added a plain-language reader guide with cited answers, re-checked FDA’s May 2026 503A nominations list, added FDA’s compounding safety-risk page and two randomized studies from our human evidence review, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include GHK-Cu.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A copper-binding peptide named in FDA's list of bulk substances under evaluation for non-injectable compounding.
    After
    A copper-binding peptide that FDA lists, except in injected forms, as under evaluation for pharmacy compounding. None of the sources reviewed reports an FDA approval.

    Evidence note

    Before
    FDA lists GHK-Cu, except injectable routes, in Category 1 for bulk substances under evaluation. That listing does not establish FDA approval, safety, or effectiveness.
    After
    Two randomized studies of copper-peptide skin and wound products report mixed results. FDA lists injected GHK-Cu among substances that may present significant safety risks. GHK-Cu is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.

    Cited source records

    Before
    fda-ghk-cu-503a-2026, fda-ghk-cu-identity
    After
    fda-ghk-cu-503a-2026, fda-ghk-cu-identity, fda-bulk-peptide-risks, journal-pmid-17147644, journal-pmid-16847171, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026

    Named organizations

    Before
    U.S. Food and Drug Administration [sources: fda-ghk-cu-503a-2026]
    After
    U.S. Food and Drug Administration [sources: fda-ghk-cu-503a-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]

    Claim citations

    Before
    name: fda-ghk-cu-identity, fda-ghk-cu-503a-2026; aliases: fda-ghk-cu-identity; category: fda-ghk-cu-503a-2026; status: fda-ghk-cu-503a-2026; summary: fda-ghk-cu-identity, fda-ghk-cu-503a-2026; evidenceNote: fda-ghk-cu-503a-2026
    After
    name: fda-ghk-cu-identity, fda-ghk-cu-503a-2026; aliases: fda-ghk-cu-identity; category: fda-ghk-cu-503a-2026; status: fda-ghk-cu-503a-2026; summary: fda-ghk-cu-503a-2026; evidenceNote: journal-pmid-17147644, journal-pmid-16847171, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
  81. Profile updated

    Ipamorelin profile

    We added a plain-language reader guide with cited answers, re-checked FDA’s ipamorelin briefing and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include ipamorelin.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    FDA's August 2024 assessment distinguishes ipamorelin free base and acetate and evaluates evidence for growth hormone deficiency and postoperative ileus.
    After
    A synthetic five-amino-acid peptide that stimulates growth hormone release and is not FDA-approved. FDA’s 2024 review found one small randomized human trial, which showed no significant benefit.

    Evidence note

    Before
    At the time of its assessment, FDA reported that neither form was a component of an FDA-approved drug and found insufficient evidence for the evaluated uses. The advisory briefing is not a final compounding determination.
    After
    FDA staff recommended in 2024 against adding ipamorelin or ipamorelin acetate to the 503A compounding list, and FDA lists ipamorelin acetate among substances that may present significant safety risks. Ipamorelin is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.

    Cited source records

    Before
    fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-ipamorelin-briefing-2024
    After
    fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-ipamorelin-briefing-2024, federal-register-2024-21241-bbe8399c5872, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026

    Named organizations

    Before
    U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]
    After
    U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]

    Claim citations

    Before
    name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-ipamorelin-briefing-2024; evidenceNote: fda-ipamorelin-briefing-2024
    After
    name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-ipamorelin-briefing-2024; evidenceNote: fda-ipamorelin-briefing-2024, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
  82. Profile updated

    Mazdutide profile

    We added a plain-language reader guide with cited answers, published trial results from our human evidence review, ClinicalTrials.gov records naming Innovent and Eli Lilly, and FDA’s current page on unapproved GLP-1 drugs, which names mazdutide. The status line keeps its cited China-only wording.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Evidence note

    Before
    These are attributable local-government reports, not the national approval decision or complete prescribing information. The national decision and exact indication conditions remain to be reconciled. This account does not establish approval in the United States or other jurisdictions.
    After
    Large randomized trials in China report weight loss and lower blood sugar. The Chinese approval is reported by local-government sources, not the national approval decision or complete prescribing information. FDA lists mazdutide among unapproved drugs it has warned companies for selling with false research-use labels.

    Cited source records

    Before
    ctg-nct07718126-v1, sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025
    After
    ctg-nct07718126-v1, sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025, fda-unapproved-glp1-concerns-2026-r2, journal-pmid-40421736, journal-pmid-41407860, journal-pmid-42628555, ctg-observation-nct06124807-2026-04-21-5c8024d25060, ctg-observation-nct07469800-2026-05-27-81ca4ac5542c, ctg-observation-nct06862908-2026-09-22-928b8a087806

    Named organizations

    Before
    West China Hospital [sources: ctg-nct07718126-v1]
    After
    West China Hospital [sources: ctg-nct07718126-v1]; Innovent Biologics [sources: ctg-observation-nct07469800-2026-05-27-81ca4ac5542c]; U.S. Food and Drug Administration [sources: fda-unapproved-glp1-concerns-2026-r2]

    Claim citations

    Before
    name: ctg-nct07718126-v1; aliases: ctg-nct07718126-v1; category: ctg-nct07718126-v1; status: sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025; summary: sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025; evidenceNote: sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025
    After
    name: ctg-nct07718126-v1; aliases: ctg-nct07718126-v1; category: ctg-nct07718126-v1; status: sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025; summary: sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025; evidenceNote: journal-pmid-40421736, journal-pmid-41407860, sipac-mazdutide-approval-report-2025, suzhou-mazdutide-indications-report-2025, fda-unapproved-glp1-concerns-2026-r2
  83. Profile status changed

    TB-500 profile

    We added FDA's July 2026 pharmacy-compounding review and changed the display status from identity-only to a pending safety review without implying a final FDA determination.

    PeptideScanner change date
    July 29, 2026
    Evidence lane
    Profile

    Status

    Before
    FDA identity record only; approval status not established
    After
    FDA compounding safety review; final determination pending

    Status classification

    Before
    identity-only
    After
    safety-review

    Topic

    Before
    Identity records
    After
    Safety records

    Profile summary

    Before
    A research-peptide name that FDA's substance registry maps to a thymosin beta-4 fragment.
    After
    A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.

    Evidence note

    Before
    FDA's substance registry identifies TB-500 as an N-terminal acetylated 17-23 fragment of thymosin beta-4 and explicitly states that a UNII record does not imply regulatory review or approval.
    After
    FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.

    Cited source records

    Before
    fda-tb-500-identity
    After
    fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026

    Named organizations

    Before
    U.S. Food and Drug Administration [sources: fda-tb-500-identity]
    After
    U.S. Food and Drug Administration [sources: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026]

    Claim citations

    Before
    name: fda-tb-500-identity; aliases: fda-tb-500-identity; category: fda-tb-500-identity; status: fda-tb-500-identity; summary: fda-tb-500-identity; evidenceNote: fda-tb-500-identity
    After
    name: fda-tb-500-identity, fda-tb-500-briefing; aliases: fda-tb-500-identity, fda-tb-500-briefing; category: fda-tb-500-briefing; status: fda-tb-500-briefing, fda-pcac-peptide-meeting-2026; summary: fda-tb-500-identity, fda-tb-500-briefing; evidenceNote: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026
  84. Profile updated

    BPC-157 profile

    We added the July 2026 FDA advisory-committee meeting context and clarified that both the committee process and the selected trial record have limited implications.

    PeptideScanner change date
    July 29, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A research peptide with FDA compounding records and a recent trial-registry entry.
    After
    A research peptide represented by FDA compounding-review material and one selected trial-registry record.

    Evidence note

    Before
    FDA's 2026 briefing says BPC-157 is not a component of an FDA-approved drug and describes limited safety information and characterization concerns. ClinicalTrials.gov also lists a recruiting study; registration is not proof of effectiveness.
    After
    FDA presented BPC-157 briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding and FDA's final determination remains pending; the cited trial registration also does not establish safety or effectiveness.

    Cited source records

    Before
    fda-bpc-157-briefing, fda-bulk-peptide-risks, ctg-nct07437547-v1
    After
    fda-bpc-157-briefing, fda-bulk-peptide-risks, ctg-nct07437547-v1, fda-pcac-peptide-meeting-2026

    Named organizations

    Before
    U.S. Food and Drug Administration [sources: fda-bpc-157-briefing]; Hudson Biotech [sources: ctg-nct07437547-v1]
    After
    U.S. Food and Drug Administration [sources: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026]; Hudson Biotech [sources: ctg-nct07437547-v1]

    Claim citations

    Before
    name: fda-bpc-157-briefing; aliases: fda-bpc-157-briefing; category: fda-bpc-157-briefing, fda-bulk-peptide-risks; status: fda-bpc-157-briefing; summary: fda-bulk-peptide-risks, ctg-nct07437547-v1; evidenceNote: fda-bpc-157-briefing, ctg-nct07437547-v1
    After
    name: fda-bpc-157-briefing; aliases: fda-bpc-157-briefing; category: fda-bpc-157-briefing, fda-bulk-peptide-risks, fda-pcac-peptide-meeting-2026; status: fda-bpc-157-briefing; summary: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026, ctg-nct07437547-v1; evidenceNote: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026, ctg-nct07437547-v1
  85. Profile updated

    Bremelanotide profile

    We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.

    PeptideScanner change date
    July 29, 2026
    Evidence lane
    Profile

    Related names

    Before
    Vyleesi
    After
    Vyleesi, PT-141

    Cited source records

    Before
    dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1
    After
    dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1, fda-bremelanotide-identity

    Claim citations

    Before
    name: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; aliases: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; category: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; status: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; summary: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; evidenceNote: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1
    After
    name: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; aliases: fda-bremelanotide-identity; category: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; status: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; summary: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; evidenceNote: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1
  86. Profile updated

    GHK-Cu profile

    We added FDA substance-identity aliases to improve search matching. The cited compounding-list status did not change.

    PeptideScanner change date
    July 29, 2026
    Evidence lane
    Profile

    Related names

    Before
    None recorded
    After
    Copper tripeptide-1, GHK copper

    Cited source records

    Before
    fda-ghk-cu-503a-2026
    After
    fda-ghk-cu-503a-2026, fda-ghk-cu-identity

    Claim citations

    Before
    name: fda-ghk-cu-503a-2026; aliases: fda-ghk-cu-503a-2026; category: fda-ghk-cu-503a-2026; status: fda-ghk-cu-503a-2026; summary: fda-ghk-cu-503a-2026; evidenceNote: fda-ghk-cu-503a-2026
    After
    name: fda-ghk-cu-identity, fda-ghk-cu-503a-2026; aliases: fda-ghk-cu-identity; category: fda-ghk-cu-503a-2026; status: fda-ghk-cu-503a-2026; summary: fda-ghk-cu-identity, fda-ghk-cu-503a-2026; evidenceNote: fda-ghk-cu-503a-2026
  87. Profile updated

    Liraglutide profile

    We added a product-name lookup term that the cited FDA label communication connects to liraglutide. The profile's status did not change.

    PeptideScanner change date
    July 29, 2026
    Evidence lane
    Profile

    Related names

    Before
    None recorded
    After
    Saxenda

    Cited source records

    Before
    dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6
    After
    dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6, fda-glp1-label-warning-request-2026

    Claim citations

    Before
    name: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; aliases: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; category: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; status: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; summary: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; evidenceNote: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6
    After
    name: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; aliases: fda-glp1-label-warning-request-2026; category: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; status: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; summary: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; evidenceNote: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6
  88. Profile updated

    MOTS-c profile

    We added FDA's dedicated briefing and advisory-committee meeting record, while preserving the pending and nonbinding nature of the review.

    PeptideScanner change date
    July 29, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A mitochondrial-derived peptide included in an FDA compounding-risk record.
    After
    A mitochondrial-derived peptide represented in FDA compounding-risk and advisory-committee records.

    Evidence note

    Before
    FDA's compounding-risk page says it has not identified human exposure data for drug products containing MOTS-c and lacks important safety information.
    After
    FDA presented MOTS-c briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.

    Cited source records

    Before
    fda-bulk-peptide-risks
    After
    fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026

    Named organizations

    Before
    U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]
    After
    U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026]

    Claim citations

    Before
    name: fda-bulk-peptide-risks; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-bulk-peptide-risks; evidenceNote: fda-bulk-peptide-risks
    After
    name: fda-mots-c-briefing; aliases: fda-mots-c-briefing; category: fda-bulk-peptide-risks, fda-mots-c-briefing; status: fda-mots-c-briefing, fda-pcac-peptide-meeting-2026; summary: fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-mots-c-briefing, fda-pcac-peptide-meeting-2026
  89. Profile updated

    Semaglutide profile

    We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.

    PeptideScanner change date
    July 29, 2026
    Evidence lane
    Profile

    Related names

    Before
    Wegovy
    After
    Wegovy, Ozempic, Rybelsus

    Cited source records

    Before
    dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026
    After
    dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026, fda-semaglutide-identity

    Claim citations

    Before
    name: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; aliases: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; category: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; status: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; summary: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026; evidenceNote: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19
    After
    name: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; aliases: fda-semaglutide-identity; category: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; status: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; summary: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026; evidenceNote: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19
  90. Profile updated

    Tirzepatide profile

    We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.

    PeptideScanner change date
    July 29, 2026
    Evidence lane
    Profile

    Related names

    Before
    Zepbound
    After
    Zepbound, Mounjaro

    Cited source records

    Before
    dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023
    After
    dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023, fda-tirzepatide-identity

    Claim citations

    Before
    name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; aliases: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38
    After
    name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; aliases: fda-tirzepatide-identity; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38
  91. Profile updated

    Abaloparatide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A parathyroid hormone-related peptide analogue represented in U.S. drug-label records.
    After
    A parathyroid hormone-related peptide analogue. This profile cites a U.S. label record.
  92. Profile updated

    Afamelanotide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A melanocortin analogue represented in current U.S. drug-label records.
    After
    A melanocortin analogue. This profile cites a U.S. label record.
  93. Profile updated

    Amycretin profile

    We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    An amylin and GLP-1 receptor agonist candidate represented in ClinicalTrials.gov.
    After
    An amylin and GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.
  94. Profile updated

    Bremelanotide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A melanocortin receptor agonist peptide represented by one exact U.S. label record.
    After
    A melanocortin receptor agonist peptide. This profile cites a U.S. label record.
  95. Profile updated

    Cagrilintide profile

    We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A long-acting amylin analogue represented in ongoing ClinicalTrials.gov records.
    After
    A long-acting amylin analogue under study. This profile cites a recruiting ClinicalTrials.gov record.
  96. Profile updated

    Dulaglutide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A GLP-1 receptor agonist represented by one exact current U.S. label record.
    After
    A GLP-1 receptor agonist. This profile cites a Trulicity label.
  97. Profile updated

    Elamipretide profile

    We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A mitochondria-targeting peptide candidate represented in ClinicalTrials.gov.
    After
    A mitochondria-targeting peptide candidate. This profile cites a recruiting ClinicalTrials.gov study record.
  98. Profile updated

    Exenatide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A GLP-1 receptor agonist represented by one exact U.S. label record.
    After
    A GLP-1 receptor agonist. This profile cites a U.S. label record.
  99. Profile updated

    Glucagon profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A peptide hormone represented by one exact current U.S. emergency-treatment label record.
    After
    A peptide hormone. This profile cites a U.S. emergency-treatment label.
  100. Profile updated

    Insulin glargine-aldy profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A long-acting insulin analogue represented by one exact current U.S. prescription-label record.
    After
    A long-acting insulin analogue. This profile cites a U.S. prescription label.
  101. Profile updated

    Lanreotide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A somatostatin analogue represented by one exact U.S. label record.
    After
    A somatostatin analogue. This profile cites a U.S. label record.
  102. Profile updated

    Leuprolide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A GnRH agonist represented by one exact U.S. label record.
    After
    A GnRH agonist. This profile cites a U.S. label record.
  103. Profile updated

    Linaclotide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A guanylate cyclase-C agonist peptide represented in current U.S. drug-label records.
    After
    A guanylate cyclase-C agonist peptide. This profile cites a U.S. label record.
  104. Profile updated

    Liraglutide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A GLP-1 receptor agonist represented by one exact current U.S. label record.
    After
    A GLP-1 receptor agonist. This profile cites a U.S. label record.
  105. Profile updated

    Lixisenatide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A GLP-1 receptor agonist component represented by one exact U.S. combination-product label record.
    After
    A GLP-1 receptor agonist component. This profile cites a U.S. combination-product label.
  106. Profile updated

    Maridebart cafraglutide profile

    We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    An antibody-peptide conjugate candidate represented in ClinicalTrials.gov.
    After
    An antibody-peptide conjugate candidate. This profile cites a completed ClinicalTrials.gov study record.
  107. Profile updated

    Mazdutide profile

    We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A metabolic peptide candidate with current ClinicalTrials.gov records.
    After
    A metabolic peptide candidate. This profile cites a ClinicalTrials.gov study record that was not yet recruiting.
  108. Profile updated

    Octreotide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A somatostatin analogue represented by one exact current U.S. label record.
    After
    A somatostatin analogue. This profile cites a U.S. label record.
  109. Profile updated

    Pemvidutide profile

    We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A glucagon/GLP-1 receptor agonist candidate with trial-registry records.
    After
    A glucagon/GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.
  110. Profile updated

    Petrelintide profile

    We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    An amylin analogue candidate represented in ClinicalTrials.gov.
    After
    An amylin analogue candidate. This profile cites a ClinicalTrials.gov study record that was not yet recruiting.
  111. Profile updated

    Plecanatide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A guanylate cyclase-C agonist peptide represented in current U.S. drug-label records.
    After
    A guanylate cyclase-C agonist peptide. This profile cites a U.S. label record.
  112. Profile updated

    Pramlintide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    An amylin analogue represented by one exact current U.S. label record.
    After
    An amylin analogue. This profile cites a U.S. label record.
  113. Profile updated

    Retatrutide profile

    We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A multi-receptor metabolic candidate with active ClinicalTrials.gov records.
    After
    A multi-receptor metabolic candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.
  114. Profile updated

    Semaglutide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A GLP-1 receptor agonist represented by an exact current Wegovy label record and an FDA notice.
    After
    A GLP-1 receptor agonist. This profile cites a Wegovy label and an FDA notice.
  115. Profile updated

    Setmelanotide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A melanocortin-4 receptor agonist represented in current U.S. drug-label records.
    After
    A melanocortin-4 receptor agonist. This profile cites a U.S. label record.
  116. Profile updated

    Survodutide profile

    We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A glucagon/GLP-1 receptor agonist candidate represented in ClinicalTrials.gov.
    After
    A glucagon/GLP-1 receptor agonist candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.
  117. Profile updated

    Teriparatide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A parathyroid hormone analogue represented in current U.S. drug-label records.
    After
    A parathyroid hormone analogue. This profile cites a U.S. label record.
  118. Profile updated

    Tesamorelin profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A growth-hormone-releasing factor analogue represented in U.S. drug-label records.
    After
    A growth-hormone-releasing factor analogue. This profile cites a U.S. label record.
  119. Profile updated

    Tirzepatide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A GIP and GLP-1 receptor agonist represented by an exact current Zepbound label record and an FDA notice.
    After
    A GIP and GLP-1 receptor agonist. This profile cites a Zepbound label and an FDA notice.
  120. Profile updated

    Vosoritide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A C-type natriuretic peptide analogue represented in current U.S. drug-label records.
    After
    A C-type natriuretic peptide analogue. This profile cites a U.S. label record.
  121. Profile updated

    Ziconotide profile

    We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

    PeptideScanner change date
    July 27, 2026
    Evidence lane
    Profile

    Profile summary

    Before
    A synthetic peptide represented in current U.S. intrathecal-drug labeling.
    After
    A synthetic peptide. This profile cites a U.S. intrathecal-drug label.

Research integrity

Source-published notices

These publisher or Retraction Watch notices are registered in the reviewed Crossref snapshot for a publication used in supervised synthesis. They are not PeptideScanner corrections and do not silently alter the preserved synthesis wording.

  1. Erratum · publisher metadata

    Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

    Crossref connects notice DOI 10.1016/s0140-6736(21)01556-7 ↗ to publication DOI 10.1016/s0140-6736(21)01324-6. Registered July 17, 2021.

    Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →

  2. Erratum · publisher metadata

    Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.

    Crossref connects notice DOI 10.1016/s2213-8587(26)00157-9 ↗ to publication DOI 10.1016/s2213-8587(26)00125-7. Registered June 19, 2026 and August 1, 2026.

    Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →

  3. Erratum · publisher metadata

    Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

    Crossref connects notice DOI 10.1016/s2213-8587(25)00399-7 ↗ to publication DOI 10.1016/s2213-8587(23)00356-x. Registered December 17, 2025 and February 1, 2026.

    Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →

  4. Correction · publisher metadata

    Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

    Crossref connects notice DOI 10.1038/s41591-026-04650-w ↗ to publication DOI 10.1038/s41591-026-04479-3. Registered August 25, 2026.

    Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →

  5. Erratum · publisher metadata

    Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial

    Crossref connects notice DOI 10.1016/s2213-8587(22)00051-1 ↗ to publication DOI 10.1016/s2213-8587(21)00296-5. Registered March 1, 2022.

    Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →

  6. Erratum · publisher metadata

    Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period

    Crossref connects notice DOI 10.1016/s2213-8587(22)00360-6 ↗ to publication DOI 10.1016/s2213-8587(22)00277-7. Registered February 1, 2023.

    Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →

How version history works

PeptideScanner checks the cited record, preserves the earlier public version, and publishes a dated notice explaining the change. A factual correction identifies the error and supporting source; a routine update is labeled separately. Every published revision above comes from the same deterministic before-and-after ledger used by the profile and recent-change pages.

Open the machine-readable correction-lineage index → It hash-binds every visible revision file to this selected public release and links adjacent changes without claiming continuous source monitoring.

Reader reports

Reporting channel status

Representatives from GoodSir Labs publish and review PeptideScanner. PeptideScanner does not yet publish a dedicated reporting channel. A verified organization-level route will appear here before the site invites submissions; no personal contact details are exposed in the meantime.